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MMP matrix metalloproteinase
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NEAA nonessential amino acids
NFκB nuclear factor kappa-B
Nkx2.5 homeobox protein Nkx2.5
NO nitic oxide
NOS nitric oxide synthase
NOS1 (or nNOS) neural nitric oxide synthase
NOS2 (or iNOS) inducible nitric oxide synthase
NOS3 (or eNOS) endothelial nitric oxide synthase
PBS phosphate buffer solution
6PI propidium iodine
PKG protein kinase G
pro-MMP2 pro-form of matrix metalloproteinase type 2
RISK reperfusion injury salvage kinase
RNS reactive nitrogen species
ROS reactive oxygen species
SAFE survivor activating factor enhancement
SEM standard error of the mean
SI/R simulated ischemia/reoxygenation
SNAP s-nitroso-n-acetyl-penicillamine
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72. INTRODUCTION
Ischemic heart disease (IHD) is one of the leading cause of death in the industrialized
world. IHD by itself is the single most common cause of death in the European Union:
accounting for over 681 000 deaths in each year (according to the European Cardiovascular
Disease Statistics, released in 2012) [1]. In Hungary, more than 6000 patients die due to the
consequences of acute myocardial infarction (AMI) in each year (according to the official
statement of the Hungarian Central Statistical Office, released in 2012) [2]. AMI leads to
massive cardiac cell loss, rapid decline of cardiac contractility, occurrence of lethal
arrhythmias, and in the long run to scar formation, structural and functional cardiac
remodeling and eventually to the development of heart failure. Therefore, it is highly
important to salvage the ischemic region of heart via its reperfusion as soon as possible to
improve the clinical outcomes of myocardial infarction. In experimental studies, the rate of
remodeling is highly affected by the extent of the infarcted area [3]. In humans, infarct size is
a major determinant of mortality in myocardial infarction [4]. Therefore, limitation of infarct
size by induction of reperfusion is an important therapeutic approach. However, reperfusion
may lead to intense generation of reactive oxygen (ROS) and nitrogen species (RNS) and
activation of numerous cascade mechanisms which may result in further myocardial damage
[5]. Additionally, despite of a decade of intense research on the cellular mechanism of
cardioprotective interventions aiming to reduce reperfusion injury, such as ischemic or
pharmacological postconditioning, the underlying mechanisms of these protective pathways
are still poorly understood. Therefore, no drug targets could be identified so far that would
lead to the development of a cardioprotective compound until market launching. This fact
urges to identify novel targets and to find effective drugs for cardioprotection.
Over the last decade, a novel therapeutic approach has been offered; stem cell derived
cardiomyocytes may be used as a cell source for cardiac repair after myocardial infarction [6–
9]. Despite the encouraging results and the enormous potential of human stem cell-derived
cardiomyocytes, several complications and ethical concerns need to be overcome towards
clinical translation. Therefore, the improvement of cell replacement therapy is one of the most
important aims of further investigations.
82.1 Pathophysiology of ischemia/reperfusion injury (I/R)
Ischemia is defined as an inadequate blood flow in the affected tissue or in an organ
that is accompanied by the loss of oxygen and nutrients. It is well known that myocardial
ischemia results in the impairment of contractile function and causes myocardial damage as a
consequence of cell death from both necrosis and apoptosis [10]. Ischemia triggers the
accumulation of intracellular sodium, hydrogen, and calcium ions, thereby facilitating tissue
acidosis (Fig.1). The decline of pH stimulates Na+-H+ exchange and Na+-HCO3- transporter,
which leads to intracellular sodium accumulation and development of intracellular Ca2+
overload [11].
Fig.1: Ischemic injury of myocardium
(modified from Ferdinandy et al., Pharmacol Rev. 2007).
Due to the impaired calcium handling, numerous intracellular enzymes are activated
including proteases and endonucleases, which are involved in proapoptotic signaling [12],
activating plasma membrane phospholipase A2, which leads to the formation of arachidonic
acid derivatives (e.g. leukotriene B4, thromboxane A2). This event then facilitates neutrophil
infiltration and perpetuates the generation of reactive oxygen radicals via stimulation of
neutrophil oxidative burst. In addition, the absence of oxygen causes cellular ATP-depletion
9that leads to mitochondrial dysfunction and initiates the translocation of Bax, a proapoptotic
Bcl2 family member protein, from the cytosol to the outer mitochondrial membrane. This
triggers mitochondrial swelling and induces the efflux of cytochrome c via opening of the
permeability transition pore (mPTP) into the cytosol [13]. The intracellularly localized
cytochrome c activates effector caspases and initiates apoptosis. The impairment of the
mitochondrial electron transport chain stimulates the generation of ROS and development of
oxidative stress in the ischemic heart. ROS react directly with cellular lipids, proteins and
DNA exacerbating cell injury/death and leading to the activation of nuclear factor kappa-B
(NFκB) [14]. Moreover, the excess of ROS impairs the antioxidant capacity of cell by
depleting reduced glutathione. Additionally, it has been also reported that intracellular ROS
(particularly peroxynitrite) are implicated with the activation of matrix metalloproteinases
(MMPs), thereby playing a pivotal role in the progression of ischemic injury by contributing
to the degradation of several extracellular matrix protein [15].
Although the re-establishment of adequate oxygen and nutrients supply is able to limit
the extent of the infarction, restoration of normal blood flow results in a complex cascade of
inflammation, sudden oxygen surplus and oxidative stress (Fig.2).
Fig.2: Reperfusion injury
(modified from Ferdinandy et al., Pharmacol Rev. 2007).
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Increasing evidence points to the fact that reperfusion injury can lead to a rapid rising
of cell necrosis and apoptosis. At reperfusion; endothelial cells up regulate the expression of
adhesive proteins and release leukocyte attractants. Activation and accumulation of
leukocytes (primarily neutrophils and monocytes) triggers multiple mediator cascades leading
to cytokine release, increased vascular permeability, generation of ROS and liberation of
proteolytic enzymes from granulocytes [10].
Additionally, during ischemia, the hydrolysis of ATP to AMP leads to the
accumulation of hypoxanthine. Increased intracellular calcium enhances the conversion of
xanthine dehydrogenase to xanthine oxidase which may produce superoxide and xanthine
from the accumulated hypoxanthine upon reintroduction of oxygen. This leads to further
oxidative stress that can jeopardize cellular function and survival [16].
2.2 Matrix metalloproteinases
Matrix metalloproteinases (MMPs) are a large family of zinc dependent endopeptidases.
They were firstly identified by Gross et al. and named according to their ability to remodel
extracellular matrix [17]. MMPs are synthesized in an inactive form (zymogen or pro-MMP),
and are activated by proteolytic cleavage of an N-terminal domain or by conformational
changes induced by denaturing agents or ROS. Basically, MMPs are activated by the removal
of the autoinhibitory propeptide domain resulting in an active truncated MMP. They are
involved in the remodeling of extracellular matrix during various physiological processes
including embryonic development [18], angiogenesis [19], wound healing and tissue repair
[20]. On the other hand, MMPs have been shown to play a crucial role in several pathologies
such as metastatic cancers [21], arthritis [22], inflammation [23] and diabetes [24]. Moreover,
gelatinase types of MMPs, (MMP-2 and MMP-9) are implicated with numerous
cardiovascular diseases such as ischemia/reperfusion injury [25,26]. It has been previously
reported that MMP-2 is constitutively expressed in cardiomyocytes [27] and stored
intracellularly in an inactive pro-MMP-2 (also referred as 72 kDa MMP-2) form. Increasing
evidences suggest that ischemic stimulus can activate the intracellular pro-MMP-2 which is
able to proteolytically cleave several structural proteins including titin, alpha-actinin, or
troponins (for recent review see ref. 28). Degradation of these proteins could lead to
contractile dysfunction and cell death. The activation of pro-MMP-2 may be due to the
increased peroxynitrite production [26]. Peroxynitrite has been shown to activate pro-MMP-2
via the redox modification of the regulatory site of this enzyme [29,30]. This redox
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modification leads to the undesired activation of 75 and 72 kDa isoforms of MMP-2, besides
that only the 64 kDa isoform is active once MMP-2 is activated in the classical manner
[31,32]. In addition, active MMP-2 is released from necrotic cells thereby exacerbating the
outcome of ischemic injury [15]. Hence, the activation of MMP-2 during an ischemic insult is
associated with decreased functional recovery and larger infarct size of the heart (for review
see ref. 33).
We have previously reported that MMP-2 activity was moderately decreased during
ischemic preconditioning [34] and that exogenous inhibition of MMPs by ilomastat, a non-
selective MMP inhibitor diminished ischemia-induced MMP-2 activity in isolated rat hearts
[35]. Furthermore, we have demonstrated that the activities of MMP-2 and MMP-9 were
decreased significantly in an in vivo rat model of ischemic late preconditioning [36].
Moreover, we and others have shown that the non-selective MMP inhibitor ilomastat reduced
infarct size in rats and mice [36,37]. Taken together, MMP-2 became a major target for drug
development in acute cardiovascular pathologies including AMI [38,39]. However it is
unknown whether ilomastat-induced cardioprotection is due to MMP-2 inhibition and what
extent of this inhibition is required for sufficient cardioprotection. Moreover it is still unclear
whether the ilomastat-iduced cardioprotection occurs via the inhibition of the intracellularly
active MMP-2.
2.3 Stem cell-derived cardiomyocytes: a new therapeutic approach to treat
myocardial infarction
Thrombolytic therapy and other coronary interventions are widely used clinical
strategies to reduce infarct size and facilitate rapid recanalization of the occluded coronary
artery after myocardial infarction to limit infarct size (for review see ref. 40). However, if
there is no adequate intervention to minimize myocardial damage, the prolonged ischemic
injury would increase the risk of mortality. Recently, an alternative approach has come into
the focus of cardiovascular regenerative medicine. Over the last few years, various cell types
such as fetal or neonatal cardiomyocytes, skeletal muscle myoblasts, mesenchymal stem cells,
hematopoietic stem cells, adult cardiac resident stem cells, embryonic stem cell-derived
cardiomyocytes have been used in preclinical studies for cell replacement therapy following
myocardial infarction (for review see ref. 41). Embryonic stem cells might be a promising cell
source, because of their capability to provide unlimited expansion in undifferentiated state and
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their ability to undergo inducible differentiation into cardiomyocytes in vitro [6–9]. However,
applications of embryonic stem cell-derived cardiomyocytes have ethical considerations;
therefore, better potential of these cardiomyocytes is testing cardioprotective compounds in
vitro. Moreover, a recently discovered technique [42] gives new insight into stem cell
biology: reprogramming of adult somatic cells into pluripotent stem cell lines (generation of
induced pluripotent stem cells) and their differentiation into functional cardiomyocytes
provides new perspectives in personalized cell replacement therapy (for review see ref. 43 and
ref. 44).
Despite the increasing number of promising results [7,8,45], several complications
need to be overcome towards clinical translation including the precise characterization of
stem cell lines, such as the development of efficient protocols for proper cardiomyocyte
differentiation, the establishment of strategies for cardiomyocyte selection, the development
of scaling-up procedures to provide clinically-relevant number of cardiomyocytes, and the
development of cell delivery strategies [43,44,46,47]. Another limitation regarding their
clinical utilization is that the survival of implanted cells is reduced after transplantation [6,8].
Implanted cells undergo a significant cell death within the first 24 hours [48]. A plausible
reason for this effect is the unfavorable microenvironment for the grafted cells when
implanted into the ischemic myocardium. Thus, in vitro preconditioning strategies might be
beneficial to improve and optimize long-term survival and maturation of the cell grafts
[49,50]. Furthermore, characterization of these cells and their hypoxic tolerance in a simulated
ischemia/reoxygenation test system would be important, since little is known about the
ischemic tolerance of stem cell-derived cardiomyocytes.
2.4 Role of nitric-oxide
Nitric oxide (NO) is a gaseous substance that regulates a wide range of biological
processes. It typically exerts its physiological functions by binding directly to ferrous iron of
heme proteins or indirectly by S-nitrosylation of protein thiol groups [51]. NO is synthesized
at low physiological levels by NO synthase (NOS) enzymes. In this reaction, L-arginine is
oxidized with molecular oxygen to form L-citrulline and NO [52]. Three main isoforms of
NOS are widely present and named according to the tissues where they were first identified or
to their mode of expression: neural NOS (nNOS or NOS1) is expressed mainly in neurons;
inducible NOS (iNOS or NOS2), the NOS isoform with the highest rate of NO synthesis
expressed in cell types of the immune system in response to infection; and endothelial NOS
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(eNOS or NOS3) is presented in the vascular endothelium. NO has a well-known
cardioprotective effect against ischemia/reperfusion injury that is conducted by activating the
cyclic guanosine monophosphate (cGMP)/ protein kinase G (PKG) axes, as a key modulator
of the RISK (reperfusion injury salvage kinase) and SAFE (survivor activating factor
enhancement) pathways, and by inducing S-nitrosylation of proteins including
sarco/endoplasmic reticulum Ca2+-ATPase and several mitochondrial proteins (for review see
ref. 51,53–57). However, excess of NO in the presence of the co-existing free radicals have
detrimental effect on cell survival.
We have previously shown that the exogenously administered NO donor S-nitroso-n-
acetyl-penicillamine (SNAP) and the particulate guanylate cyclase activator B-type natriuretic
peptide (BNP) exert cytoprotective effect against simulated ischemia/reoxygenation (SI/R)
injury in primary neonatal rat cardiomyocytes [58]. This protection acts via the activation of
cGMP/PKG signaling pathway, thereby stimulating its multiple downstream signal
transduction cascade which leads to increased cell viability against SI/R injury [59,58,60].
Moreover, our previous findings also suggest that the present screening platform is a useful
tool for discovery of cardiocytoprotective molecules and investigate their cellular
mechanisms. Nevertheless, the importance of the cardioprotective effect of the activation of
cGMP-PKG axes in mouse ESC (mESC)-derived cardiomyocytes is still unknown. Thus, it
would be beneficial to test this pathway in the previously established SI/R test system.
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3. AIMS
Study 1
We aimed to test whether ilomastat-induced cardioprotection is due to (and what
extent of) MMP-2 inhibition, we performed gelatin zymography and in situ zymography
followed by immunostaining of MMP-2 in primary neonatal rat cardiomyocytes exposed to
SI/R injury. Furthermore, our goal was to investigate the dose-response effect of ilomastat
administered before the onset of ischemia as well as before the onset of reperfusion in an in
vivo rat model of myocardial infarction.
Study 2
The aim of the second study was to establish a mouse embryonic stem cell-derived
cardiomyocyte–based drug screening platform by investigating whether the cytoprotective
NO-donor SNAP and B-type natriuretic peptide is able to protect these cells against SI/R
injury. We also investigated the downstream pathways of the protection in this platform.
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4. MATERIALS AND METHODS
Animal handling and the investigation was in conjunction with Guide for the Care and
Use of Laboratory Animals published by the U.S. National Institutes of Health (National
Institutes of Health publication 85-23, revised 1996), and it was approved by a local animal
ethics committee.
4.1 Experimental design of Study 1
4.1.1 Animals
Male Wistar rats (Charles-River, Germany) weighing 280-370g were used in the
experiments housed in individually ventilated cages. Animals were fed with standard murine
chow and unlimited access to water was ensured prior to the surgical intervention. For the cell
culture experiments, neonatal Wistar rats were purchased from the local live-stock of the
University of Szeged.
4.1.2 Experimental design of in vitro studies
4.1.2.1 Inhibition of gelatinase activity by ilomastat
To determine the source of the gelatinolytic activity and its inhibition by ilomastat,
gelatin zymography was performed on cardiac tissue homogenate of a non-treated control rat.
Gelatinolytic activities of MMP-2 were examined as previously described in detail by Kupai
et al. [31]. Briefly, 8% polyacrylamide gels were copolymerized with gelatin (2 mg/mL, type
A from porcine skin, Sigma-Aldrich, Budapest, Hungary), and 50 µg of protein per lane were
loaded. After electrophoresis (90 V, 1.5 h), gels were washed with renaturation buffer (Bio-
Rad, Hercules, CA; containing 2.5% Triton X-100) for 3×15 min then incubated in
development buffer (Bio-Rad, Hercules, CA) for 20 min to eliminate Triton-X-100. Gels were
sliced according to the lanes and the slices were incubated separately for 20 h at 37°C (pH
7.4) in development buffer in the presence of vehicle and/or different concentrations of
ilomastat (0.5 nM and 5.0 nM). Recombinant, human MMP-2 was used as positive control.
Gels were then stained with 0.05% Coomassie brilliant blue (G-250, Sigma-Aldrich,
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Budapest, Hungary). Gelatinolytic activities were detected as transparent bands against the
dark-blue background. Band intensities were quantified (Quantity One software, Bio-Rad,
Hercules, CA) and expressed in arbitrary units. The gelatin zymography protocol does not
contain any component or step, which may inhibit proteases including other MMPs.
4.1.2.2 Simulated ischemia/reoxygenation in cardiomyocytes
Neonatal rat cardiomyocytes were cultured in 48-well plates. Neonatal
cardiomyocytes were chosen for this study, as they can be harvested on culture dishes without
coating. The lack of coating is important in the present study, as coating materials (e.g.
laminin, collagen, etc.) could influence the action of matrix metalloproteinases [61,62]. Cell
isolation, culturing method and the SI/R drug screening platform were described before in
detail [58,63]. Briefly, neonatal rats were sacrificed by cervical dislocation and hearts were
placed into ice cold PBS solution. Ventricles were digested in 0.25% trypsin (Invitrogen, Life
Technologies Hungary, Budapest, Hungary) solution and cell suspension was centrifuged at
400×g, for 15 min at 4°C. Cell pellet was re-suspended in Dulbecco's Modified Eagle
Medium (DMEM, Sigma-Aldrich, Budapest, Hungary) supplemented with L-glutamine
(Sigma-Aldrich, Budapest, Hungary), Antibiotic-antimycotic solution (Sigma-Aldrich,
Budapest, Hungary) and 10% fetal bovine serum (FBS, Gibco, Life Technologies Hungary
Ltd, Budapest, Hungary). Cells were counted in a hemocytometer, and seeded into 48-well
plates at a density of 5×104 cell/well. After 24 hours, the growth medium was replaced with
differentiation medium containing 1% fetal bovine serum. Cardiomyocytes were kept under
normoxic conditions (95% air and 5% CO2 at 37°C) for three days prior to SI/R experiments.
We used a combination of hypoxic chamber and hypoxic solution to simulate tissue ischemia
[58]. In the simulated ischemic group, the medium of the cultures were replaced with a
hypoxic solution [58,64] and plates were kept in a hypoxic chamber (gassed with 95% N2 and
5% CO2 at 37°C) for 240 min in the presence or absence of ilomastat (5 nM, 50 nM 500 nM
and 5 µM). The vehicle group was treated only with 0.2% DMSO. During reoxygenation,
cells were covered with differentiation medium (containing 1% fetal bovine serum) and kept
in a normoxic incubator for 120 min (Fig.3).
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Fig.3: Experimental protocol for testing the direct cardioprotective effect of ilomastat in isolated neonatal rat
cardiomyocytes exposed to SI/R injury.
4.1.2.3 Cell viability assay
Cell viability was assessed by a calcein and propidium iodine (PI) assay performed in
each group after 2 h simulated reperfusion. Briefly, the growth medium was removed; cells
were washed with PBS twice and incubated with calcein (1 μM) for 30 min. Then calcein
solution was replaced with fresh PBS and fluorescence intensity of each well was detected by
fluorescent plate reader (FluoStar Optima, BMG Labtech, Auro-Science Consulting Ltd,
Budapest, Hungary; scan matrix: 10×10; scan diameter: 10 mm; bottom optic; number of
flashes/scan point: 3; temp: 37°C; excitation wavelength: 488 nm; emission wavelength: 520
nm). Then to assess total cell count in each well, PI (50 μM) and digitonin (100 μM) (Sigma-
Aldrich, St. Louis, MO) were dissolved in PBS and cells were incubated in this solution for 7
minutes. Then PI solution was replaced with fresh PBS and fluorescent intensity was detected
with same settings (excitation wavelength: 544 nm; emission wavelength: 610 nm). Calcein
data were normalized to total cell count obtained by PI+ digitonin treatment.
4.1.2.4 In situ zymography and MMP-2 co-localization
To detect in situ MMP-2 activity [65], neonatal rat cardiomyocytes were cultured in
24-well tissue culture plate at the density of 105 cells/well for 3 days. The medium of cells
was replaced with hypoxic solution supplemented with DQ™ gelatin (Invitrogen, Life
Technologies Hungary Ltd, Budapest, Hungary) at 40 μg/mL concentration. Cells were then
subjected to 240 min simulated ischemia in the presence of ilomastat (at 500 nM
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concentration) or its vehicle. Other series of cells were covered with normoxic solution and
kept in normoxic incubator for 240 min. Subsequently, all groups were subjected to
reoxygenation: the hypoxic, or normoxic solution of the cells was replaced with
differentiation medium supplemented with DQ™ gelatin and cells were placed into a
normoxic incubator for 120 min. Finally cells were washed with PBS, and fixed in 3.7%
paraformaldehyde dissolved in PBS for 15 min. MMP-2 fluorescent immunostaining using
anti-proMMP-2 antibody (Chemicon, MAB3308; Merck Ltd, Budapest, Hungary; secondary
antibody: rhodamine-labeled goat anti-mouse antibody; Abcam, AB5885, Cambridge, UK)
was assessed to detect co-localization of MMP-2 with gelatinolytic activity. Nuclei of the
cells were stained with Hoechst 33342 (Invitrogen, Life Technologies Hungary Ltd,
Budapest, Hungary). After the subsequent washing steps, cells were covered with fluorescent
mounting medium (Dako, Frank Diagnosztika Ltd, Budapest, Hungary), and fluorescence was
detected with a confocal laser microscope in sequential scanning mode (Olympus Fluoview
1000, Olympus Hungary Ltd, Budapest, Hungary). Assessment of the gelatinolytic activity
was carried out by quantifying different parameters of fluorescent particles from 10 fields
selected randomly on each coverslip. Four coverslips were analyzed in each group. The
number, total area, and area fraction of fluorescent signal, and the analyses of co-localization
were quantified on images by ImageJ 1.45 software (National Institutes of Health, Bethesda,
MD).
4.1.3 Experimental design of in vivo studies
4.1.3.1 Surgical procedure of coronary occlusion
Rats were anesthetized by intraperitoneal injection of 60 mg/kg sodium pentobarbital
(Euthasol, Produlab Pharma b.v., Raamsdonksveer, The Netherlands). Animals were then
intubated and mechanically ventilated (Model 683, Harvard Apparatus, Holliston, MA) with
room air in a volume of 6.2 mL/kg and a frequency of 55±5 breath/min according to their
body weight. Rats were placed in supine position on a heating pad to maintain body core
temperature in physiological range (37.0°C±1.0°C). Right carotid artery was cannulated to
measure mean arterial blood pressure by a pressure transducer (Experimetria Inc., Budapest,
Hungary). Mean arterial blood pressure and electrocardiogram (ECG) was continuously
monitored throughout the experiments (Haemosys, Experimetria Inc., Budapest, Hungary).
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Right jugular vein was also cannulated for fluid substitution and drug administration. Left
anterior descending coronary artery (LAD) occlusion was induced by left thoracotomy. A 5-0
Prolene suture (Ethicon, Johnson & Johnson, Budapest, Hungary) was placed around LAD
artery and a small plastic knob, which was threaded through the ligature and placed onto the
heart, was used for making occlusion for 30 minutes. Appearance of ischemia was confirmed
by ST segment elevation and arrhythmias. After 30-min ischemia, hearts were reperfused for
120 min by releasing the ligature. Restoration of blood flow was confirmed by arrhythmias
observed in the first minutes of reperfusion.
4.1.3.2 Experimental groups
In first series of in vivo experiments, ilomastat was administered before the onset and
during the 30-min ischemia. Animals were divided into five groups. Dimethyl sulfoxide
(DMSO), 11.6 w/v% solution diluted with physiological saline) as vehicle or 0.3, 0.75, 1.5,
and 3.0 µmol/kg ilomastat were administered intravenously in slow bolus 5 minutes before
ischemia (Fig.4, shaded arrow). To maintain serum level of ilomastat, additional 3 boluses of
vehicle (5.8% DMSO solution) or ilomastat with half dose (0.15, 0.375, 0.75; and 1.5
µmol/kg, respectively), were given at the 10th, 25th min of ischemia and at the 10th min of
reperfusion (Fig.4, open arrows). We estimated the maintaining doses of ilomastat according
to its half-life based on pharmacokinetic data described previously in rodents after a single
intravenous bolus injection [66].
Fig.4: In vivo experimental protocol for testing the cardioprotective effect of ilomastat when administered before
ischemia. Shaded arrow indicates the loading dose of ilomastat, whereas open arrows show the maintaining
doses.
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In the second series of in vivo experiments DMSO (11.6 m/v% solution) or ilomastat
(0.75, 1.5, 3.0, and 6.0 µmol/kg) bolus was injected at the 25th min of ischemia (Fig.5).
Maintaining boluses (5.8% DMSO or 0.375, 0.75, 1.5, and 3.0 µmol/kg, respectively) were
administered at the 10th, 25th and 40th min of reperfusion (Fig.5) to maintain constant
ilomastat concentration in blood during the early phase of reperfusion.
Fig.5: In vivo experimental protocol for testing the cardioprotective effect of ilomastat when administered before
reperfusion. Shaded arrow indicates the loading dose of ilomastat, whereas open arrows show the maintaining
doses.
4.1.3.3 Determination of infarct size
At the end of reperfusion hearts were isolated for infarct size measurements. Hearts
were retrogradely perfused in a Langendorff perfusion system with 37°C Krebs-Henseleit
buffer [67] to remove blood from the coronary vessels. After 5 min of perfusion, risk area was
re-occluded, and hearts were perfused with 4 mL of 0.1% Evans blue dye through the
ascending aorta. Following Evans staining, hearts were cut into 5 transversal slices and
incubated in 1% triphenyl-tetrazolium-chloride for 10 min at 37°C followed by formalin
fixation for 10 min. Planimetric evaluation was carried out to determine infarct size using
InfarctSize™ software, [68].
4.1.4 Statistical analysis
Statistical analysis was performed using Sigmaplot 11.0 software. All data were given
as mean ± standard error of the mean (SEM). One-way ANOVA followed by Fisher-LSD post
hoc tests were performed to show differences among groups. P values of ≤0.05 were accepted
as statistically significant difference compared to vehicle control.
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4.2 Experimental design of Study 2
4.2.1 Mouse Embryonic Stem Cell Culture
Undifferentiated mouse embryonic stem cells (mESCs) (Nkx2.5/EGFP transgenic
C57BL/6 mouse ES cell line; TgNkx2.5/EGFP C57BL/6; passages 10-12) were cultured on feeder
layers of mitomycin C-inactivated mouse embryonic fibroblasts (MEFs) which were obtained
from 13.5 days postcoitus mouse embryos as described earlier [69]. mESCs were maintained
in ES medium (DMEM) supplemented with 15% (v/v) FBS (Sera Laboratories International,
West Sussex, RH17 5PB, UK), 1000 U/mL mouse leukemia inhibitory factor (LIF, ESGRO,
Chemicon International, Budapest, Hungary), 0.1 mM nonessential amino acids (NEAA), 0.1
mM β-mercaptoethanol (β-ME) and 50 U/mL penicillin / 50 µg/mL streptomycin. mESCs
were cultured on feeder layers for at least two passages after thawing and subsequently were
cultured without feeder cells on 0.1 % gelatin-coated tissue culture plates in the presence of
LIF (2000 U/mL). Medium was changed daily for standards maintenance. mESCs were
usually passaged every 1-2 days prior reaching 70% confluences.
4.2.2 Embryoid Body (EB) Formation and Cardiomyocyte Differentiation
mESCs were dissociated from monolayer culture with 0.05% trypsin-EDTA into a
single cell suspension. EBs were produced by using the hanging drop method [70]; Briefly,
mESCs were resuspended at the density of 4x104 cells/mL in differentiation medium (regular
DMEM without LIF) resulting in 800 cells/drop. Two days later, the EBs were transferred and
seeded into 24 well plates on gelatin coated coverslips. 0.1 mg/ml ascorbic acid was presented
in the medium to induce cardiac differentiation. mESC-derived cardiomyocytes were used at
6-8 day-old stage for simulated ischemia/reoxygenation experiments. At this stage, the ratio
of Nkx2.5-eGFP positive cells, an early marker for cardiac differentiation, exhibited
52.5±10% eGFP positivity (n=30). The cells were fluorescently imaged and analyzed by
using Digital Image Processing Software (AxioVision 4.8.1, Carl Zeiss MicroImaging GmbH,
Germany).
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4.2.3 Experimental Groups
For cell SI/R experiments, mESC-derived cardiomyocytes were tested under normoxic
condition or were subjected to SI (Fig.6).
Fig.6: Experimental protocol for testing cardioprotective compounds in a stem-cell-based a drug screening.
The normoxic mESC-derived cardiomyocytes were kept under normoxic conditions;
the growth medium was changed to a normoxic solution [58,64] and the cells were incubated
under 95% air and 5% CO2 at 37 °C for 150 min. In the second series of experiments, mESC-
derived cardiomyocytes were subjected to SI by incubating cells in hypoxic solution [58,64]
and placing the plates in a humidified 37°C hypoxic chamber exposed to a constant flow of a
mixture of 95% N2 and 5% CO2 for 150 min. The cells were then subjected to the following
treatments during SI or normoxic condition: (1) untreated control; (2) SNAP (0.1 µM, 1 µM,
10 µM; Sigma;St. Louis, MO) [58]; (3) selective PKG inhibitor KT-5823 (60 nM, an effective
concentration that does not affect cell viability alone; Sigma, St. Louis, MO) [58]; (4) SNAP
(1 µM, a concentration found here protective) in combination with KT-5823 (60 nM); (5) the
particulate guanylate cyclase activator BNP (1 nM, 10 nM, 100 nM; American Peptides,
Sunnyvale, CA) [71]; (6) the nitric oxide synthase (NOS) inhibitor N-Nitro-L-arginine (L-
NNA; 100 µM, 10 µM; Sigma, St. Louis, MO) [72]; (7) the non-selective KATP channel
inhibitor glibenclamide (1 µM, an effective KATP blocking concentration that does not affect
ischemia/reperfuion injury alone; Sigma, St. Louis, MO) [73]; (8) SNAP (1 µM) and
glibenclamide (1 µM); and DMSO (Sigma, St. Louis, MO) control groups.
Either normoxic or SI treatments were followed by 120 min reoxygenation with
growth medium without ascorbic acid and superfusion with 95% air and 5% CO2 at 37 °C.
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4.2.4 Cell Viability Assay
Cell viability was assessed by a PI assay performed in each group after 120 min
reoxygenation. PI was chosen, as it stains cells with severely impaired membrane integrity
and it does not necessitate dissociation of the cells. Briefly, the growth medium was removed,
cells were washed with PBS twice and incubated with PI (50 μM; Sigma, St. Louis, MO) for
7 minutes. Each experiment included a digitonin (10 μM; Sigma, St. Louis, MO) treated
positive control well and PI control (mESC-derived cardiomyocytes without treatment and
stained for PI for 7 min) (Fig.14). Then PI solution was replaced with fresh PBS and
fluorescence intensity of each EB was detected by fluorescent plate reader (FluoStar Optima,
BMG Labtech). Fluorescence intensity was measured in well scanning mode (scan matrix:
10x10; scan diameter: 10 mm; bottom optic; number of flashes/scan point: 3; temp: 37°C;
excitation wavelength: 544 nm; emission wavelength: 610 nm). PI intensity reflecting the cell
death was evaluated on a standard area (21 scan box) in each well placed to the center of EB.
The cardiomyocyte-rich region can be found predominantly near the edge of the embryonic
body. Therefore, the evaluation of cardiac myocyte rich regions was performed manually on
several plates by detecting eGFP expression driven by the promoter of the early cardiac
myocyte marker Nkx2.5. The ratio of cardiac myocyte death was the same as the ratio of cell
death of all cells found in the embryonic body. Background fluorescence intensity (dye
control) was subtracted from the fluorescence intensity of each well after PI staining, and the
average intensity of each group was plotted. The cytoprotective effect of different compounds
was compared to simulated ischemic control groups.
4.2.5 Statistical Analysis
Results are expressed as mean ± SEM. One way analysis of variance (ANOVA)
followed by Fisher’s least significant difference (LSD) post-hoc tests was used to determine
differences in mean values between groups. In case comparison of two groups, unpaired t-test
was used. Differences were considered significant at p<0.05.
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5. RESULTS
5.1 Results of Study 1
5.1.1 Effect of ilomastat on cardiac gelatinolytic activity
In a preliminary series of studies, the in vitro MMP-inhibitory dose range of ilomastat
was estimated in rat cardiac tissue homogenate by gelatin zymography. We have found that
the IC50 of ilomastat was 0.83 nM. Gelatinolytic activity was detectable only at 72 kDa in
cardiac homogenate suggesting that only MMP-2 activity was present in the heart tissue at a
significant level (Fig.7).
Fig.7: Representative images of MMP-2 activity in rat cardiac tissue homogenate
in the presence of 0; 0.5 and 5.0 nM ilomastat.
5.1.2 Effect of ilomastat on cardiomyocytes injured by ischemia/reoxygenation
In order to test if a direct cardiocytoprotection by MMP-2 inhibition of ilomastat is
involved in its cardioprotective effect, we examined ilomastat-induced cytoprotection in
primary neonatal rat cardiomyocytes subjected to normoxia or SI/R (Fig.3). Ilomastat at a
concentration range of 0.5 nM up to 5 µM did not influence cell viability in normoxic
conditions (Table 1). However, ilomastat at 500 nM and 5 µM significantly increased cell
viability as compared to vehicle treated group (from 8.6±0.3 to 9.8±0.4 and 9.7±0.2,
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respectively, expressed in arbitrary units of fluorescent intensity) in neonatal rat
cardiomyocytes exposed to SI/R injury (Fig.8).
Fig.8: Effect of ilomastat on cell viability of neonatal rat cardiomyocytes after SI/R.
Data are expressed as mean ± SEM; n=6; one-way ANOVA followed by Fischer LSD posthoc test; *p<0.05
compared to vehicle treated group.
Table 1: Effect of ilomastat on cell viability of neonatal rat cardiomyocytes after 240 min normoxia (suitable for
the hypoxic period) followed by 120 min reoxygenation. Data are expressed as mean±SEM; n=5-6; one-way
ANOVA followed by Fischer LSD posthoc test.
Table 1: Effect of ilomastat on cell viability of neonatal rat
cardiomyocytes after 240 min normoxia
Cell viability (% of vehicle control)
vehicle 100±4
ilo 0.5 nM 102±6
ilo 5 nM 92±5
ilo 50 nM 104±10
ilo 500 nM 105±9
ilo 5 µM 97±8.3
medium control 115±7
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5.1.3 In situMMP-2 inhibition by ilomastat in cardiomyocytes injured by
ischemia/reoxygenation
To test the in situ MMP inhibitory efficacy of the cardiocytoprotective concentration
of ilomastat, we performed in situ zymography on isolated neonatal rat cardiomyocytes
subjected to SI/R (Fig.9).
Fig.9: Representative fluorescent confocal images from neonatal rat cardiomyocytes subjected to normoxia, SI,
or SI in the presence of 500 nM ilomastat. Green color represents MMP-2 activity as measured by in situ
zymography FITC signal; blue color shows the nuclei of the cells. Scale bars = 20 µm.
SI/R injury increased gelatinolytic activity significantly from its control value of 0.48±0.04%
to 0.93±0.05% of area fraction. The cardiocytoprotective concentration of ilomastat (500 nM,
see Fig.8) moderately inhibited the in situ gelatinolytic activity approximately by 25%, i.e.
from 0.93±0.05% to 0.70±0.04% of area fraction, during SI/R (Fig.10).
Fig.10: Effect of ilomastat on intracellular gelatinolytic activity in neonatal rat cardiomyocytes after SI/R.
Data are expressed as mean ± SEM; n=6; one-way ANOVA followed by Fischer LSD posthoc test; *p<0.001
compared to normoxic vehicle-treated group; #p<0.01 compared to simulated ischemia/reperfusion, vehicle-
treated group,
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Moreover, we performed separate experiments to show co-localization of MMP-2 with the
fluorescent gelatinolytic signal in isolated neonatal rat cardiomyocytes exposed to SI/R injury.
MMP-2 showed over 90% co-localization rate with gelatinolytic activity in all groups
(Fig.11).
Fig.11: Representative confocal images of cultured neonatal rat cardiomyocytes exposed to normoxia or SI in
the presence or absence of ilomastat (500 nM). Green fluorescence: fluorescent signal of gelatin substrate after
proteolytic cleavage. Red fluorescence: MMP-2 immunostaining, Blue fluorescence: cell nuclei.
Scale bars = 20 µm
5.1.4 Effect of ilomastat on infarct size in vivo
The cardioprotective effect of ilomastat administered before the onset of ischemia
(Fig.4) or before the onset of reperfusion (Fig.5) was studied in an in vivo myocardial
infarction model induced by coronary occlusion in rats. When administered before the onset
of ischemia, ilomastat at 0.75 and 1.5 µmol/kg doses reduced infarct size significantly as
compared to vehicle-treated group (from 66.1±4.6% to 45.3±7.0% and 46.7±5.5% of area at
risk, respectively) showing a U-shaped dose-response relationship (Fig.12). When
administered before the onset of reperfusion, ilomastat at 6.0 µmol/kg reduced infarct size
significantly (from 65.4±2.5% to 52.8±3.7% of area at risk), however, lower doses were
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ineffective (Fig.13). There were no significant differences in the area at risk among the groups
(data not shown). There were no significant differences in the mean arterial blood pressure
and heart rate among the groups (Table 2 and Table 3) as well.
Fig.12: Effect of ilomastat treatment on infarct size when administered before ischemia.
Data are shown as mean ± SEM; n=7-8; one-way ANOVA followed by Fischer LSD posthoc test; *p<0.05
compared to vehicle-treated group.
Fig.13: Effect of ilomastat treatment on infarct size when administered before reperfusion.
Data are shown as mean ± SEM; n=7-8; one-way ANOVA followed by Fischer LSD posthoc test; *p<0.05
compared to vehicle-treated group.
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Table 2: Effects of ilomastat treatment on mean arterial blood pressure and heart rate when administered
before the onset of ischemia. Data are expressed as mean ± SEM; n=7-8; one-way ANOVA followed by Fischer
LSD posthoc test.
Table 2: Effects of ilomastat treatment on mean arterial blood pressure and heart rate when
administered before the onset of ischemia.
Mean arterial blood
pressure (mmHg) Baseline
30th min of
ischemia
120th min of
reperfusion
vehicle 121.1±6.7 82.4±6.6 73.1±1.7
ilo 0.3 µmol/kg 118.6±4.4 76.5±6.1 73.6±4.8
ilo 0.75 µmol/kg 117.5±2,3 90.5±3.0 77.6±7.1
ilo 1.5 µmol/kg 118.1±5.9 75.9±3.7 58.3±5.3
ilo 3.0 µmol/kg 120.0±4.7 80.5±8.5 71.2±6.0
Heart Rate (beats/min)
vehicle 408±7 392±16 373±9
ilo 0.3 µmol/kg 398±10 374±21 378±18
ilo 0.75 µmol/kg 441±20 422±11 390±16
ilo 1.5 µmol/kg 400±14 388±24 410±15
ilo 3.0 µmol/kg 449±20 400±17 401±27
Table 3: Effects of ilomastat treatment on mean arterial blood pressure and heart rate when
administered before the onset of reperfusion
Mean arterial blood
pressure (mmHg) Baseline
30th min of
ischemia
120th min of
reperfusion
vehicle 114.1±4.3 87.3±5.1 77.7±5.2
ilo 0.75 µmol/kg 127.5±3.6 91.3±7.4 83.1±5.3
ilo 1.5 µmol/kg 111.8±5.4 86.8±6.5 81.3±5.3
ilo 3.0 µmol/kg 112.6±4.3 97.4±6.7 74.4±6.8
ilo 6.0 µmol/kg 104.1±6.7 80.2±9.0 83.6±6.3
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Table 3: Effects of ilomastat treatment on mean arterial blood pressure and heart rate when administered
before the onset of reperfusion. Data are expressed as mean ± SEM; n=10-18; one-way ANOVA followed by
Fischer LSD posthoc test.
Heart Rate (beats/min)
vehicle 408±14 424±10 406±11
ilo 0.75 µmol/kg 429±15 424±14 392±15
ilo 1.5 µmol/kg 402±15 387±10 396±11
ilo 3.0 µmol/kg 423±15 412±14 392±15
ilo 6.0 µmol/kg 444±13 417±17 411±13
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5.2 Results of Study 2
5.2.1 Cell Viability after SI/R treatment of mESC-derived cardiomyocytes
We applied SI/R to mimic in vivo ischemia/reperfusion injury in mESC-derived
cardiomyocytes. 150 min of SI followed by 120 min reoxygenation caused significantly
higher cell death in mESC-derived cardiomyocytes than time-matched controls kept under
normoxic conditions (Fig.14).
Fig.14: Cell viability of mESC-derived cardiomyocytes subjected to normoxia or SI. Background fluorescence
intensity is represented by using non-treated EB + PI in three wells. PI+ digitonin control alone was applied in
one well. Data are expressed as mean ± SEM; n=5-6; unpaired t-test; * p<0.05 compared to normoxic group
Simulated ischemia killed roughly 20-40% of cells in embryonic body. The cytoprotective
action of the NO donor SNAP that activates soluble guanylate cyclase was tested in this
model of SI and reoxygenation-induced cell death in mESC-derived cardiomyocytes. Cell
death was significantly decreased by SNAP in a concentration-dependent manner (1 µM and
10 µM, vs. vehicle control, p<0.05) when applied during SI period (Fig.15). The contribution
of endogenous NO production of mESC-derived cardiomyocytes to cell death during SI was
tested by administration of the non-selective NOS inhibitor L-NNA at 10 µM and 100 µM
concentration. The presence of L-NNA did not influence cell death after SI (Fig.16).
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Fig.15: Effect of SNAP on cell viability of mESC-derived cardiomyocytes.
Data are expressed as mean ± SEM; n=10-12; one-way ANOVA followed by Fischer LSD posthoc test;
* p<0.05 compared to SI control.
BNP, an activator of particulate guanylate cyclase was also tested under SI condition at 1 nM,
10 nM and 100 nM concentrations. However, BNP did not influence cell death significantly
(Fig.17).
Fig.16: Effect of L-NNA on cell viability of mESC-derived cardiomyocytes.
Data are expressed as mean ± SEM; n=10-12
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Fig.17: Effect of BNP on cell viability of mESC-derived cardiomyocytes.
Data are expressed as mean ± SEM; n=10-12
In separate experiments, the downstream pathways of SNAP-induced protection of mESC-
derived cardiomyocytes were studied (Fig.18).
Fig.18: Effect of PKG (KT) and KATP (Glib) inhibitor on cell viability of mESC-derived cardiomyocytes.
Data are expressed as mean ± SEM; n=10-12; one-way ANOVA followed by Fischer LSD posthoc test;
* p<0.05 compared to SI control.
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The cytoprotective effect of SNAP (at 1 µM) was attenuated either by simultaneous
administration of the selective PKG inhibitor KT-5823 (60 nM) or by simultaneous
administration of KATP channel inhibitor glibenclamide (1 µM). Inhibitors administered alone,
or their vehicle DMSO did not influence cell viability (Fig. 18).
In time-matched normoxic control groups, none of the above treatment influenced cell
viability significantly (data not shown).
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6. DISCUSSION
6.1 Study 1: MMP-2 inhibition by ilomasat exerts cardioprotection
In study 1 we have demonstrated that an approximately 25% inhibition of intracellular
MMP-2 activity by the non-selective MMP inhibitor ilomastat confers significant
cardiocytoprotection. Moreover, ilomastat reduced infarct size when administered either
before the onset of ischemia or before the onset of reperfusion in vivo and revealed its
cardioprotective dose-response relationship. This is the first demonstration that the
cardioprotective effect of ilomastat may involve a cardiocytoprotective mechanism due to a
moderate inhibition of MMP-2.
Endogenous cardioprotection by early and late ischemic preconditioning as well as
postconditioning might act via MMP-2 inhibition [34–36,74]; Bell et al. reported that
ilomastat protects the heart against reperfusion injury independently from the well-known
cardioprotective cellular RISK/mPTP modulating pathways [37]. Since ilomastat is a non-
selective MMP inhibitor, therefore, the question has arose, inhibition of which MMP
isoenzyme was responsible for the cardioprotective effect of ilomastat. To answer this
question, here we performed gelatin zymography from cardiac homogenates isolated from
untreated rats and used purified MMP-2 enzyme to identify the MMP-2 specific activity in the
zymogram. Gelatinolytic activities at 72 and 64 kDa were detected according to the molecular
weights of the two active isoforms of MMP-2. Bands of other molecular weights were not
observed on the zymogram which is in line with our previous finding reported by Kupai et al.
[31].
Recently, a large number of studies focused on the intracellular actions of MMP-2,
that can degrade several newly identified intracellular targets including cardiac troponin I,
myosin light chain-1, α-actinin (for review see ref. 28). The degradation of myocardial
contractile proteins is an early event in myocardial infarction; which may contribute to the
induction of proapoptotic cascades in cardiomyocytes and thus leads to cell death and
contractile dysfunction [75]. Therefore, here we tested the direct cytoprotective effect of
ilomastat in a previously established drug screening platform using isolated neonatal rat
cardiomyocytes exposed to SI/R injury [58]. Our results clearly show that ilomastat exerts
direct cytoprotective effect via attenuating the intracellularly active MMP-2 activity as proved
by in situ zymography whereas, gelatinolytic activity was co-localized with MMP-2
immunostaining. Additionally, we have previously shown that MMP-2 activity can be
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detected in both intact and in ischemia/reperfused rat ventricular samples [35]. Thus, MMP-2
is suspected to be the only MMP isoform with gelatinolytic activity in the rat myocardium.
This is in accordance with previous findings by others, who have shown that MMP-2
possesses a predominant expression in both animal and human cardiomyocytes and cardiac
tissue [27,76]. Therefore, the presenting results suggest that gelatinolytic activity in the heart
is originated solely from MMP-2. Nevertheless, it cannot be excluded that inhibition of other
non-gelatinolytic proteases may be involved in the cardiocytoprotective effect of ilomastat.
Moreover, here we further tested the magnitude of MMP-2 inhibition necessary for
cardioprotection and found that the cardiocytoprotective dose of ilomastat inhibited MMP-2
activity only by 25%. Previously we have demonstrated that cardioprotection by late ischemic
preconditioning reduced MMP-2 activity by approximately 20% [36]. Our present study
suggests that a moderate MMP-2 inhibition is sufficient for cardioprotection. Due to the well-
known side effects of MMP inhibitors including tendonitis-like fibromyalgia and
musculoskeletal syndrome [39,77], it is of great clinical importance that possibly there is no
need for high efficacy MMP inhibitors to protect the heart against ischemia/reperfusion
injury.
We further investigated the cardioprotective effect of ilomastat in an in vivo rat heart
model of myocardial infarction. Ilomastat reduced infarct size dose-dependently when
administered either before ischemia or before reperfusion. We have found a different dose
range between this two administration protocols. When administered before the onset of
ischemia, the effective doses of ilomastat were 0.75 and 1.5 µmol/kg, however, higher doses
of ilomastat were not significantly effective. Nevertheless, when ilomastat was administered
before the onset of reperfusion, 6 µmol/kg ilomastat was found to decrease infarct size, and
lower doses were ineffective. This is the first demonstration that the cardioprotective dose
ranges of ilomastat, when administered before ischemia or before reperfusion, were not
overlapping in vivo. Our present results are supported by previous studies describing that
Zn2+-binding type MMP inhibitors, such as doxycycline and o-phenantroline, improved
cardiac mechanical function after ischemia/reperfusion injury via the inhibition of MMP-2 in
isolated rat hearts [25,78,79]. We have recently shown that the intravenously injected ilomasat
(at 1.5 µmol/kg, administered before the onset of ischemia) decreased infarct size and had a
comparable cardioprotective effect to ischemic late preconditioning [36]. More recently, Bell
and colleagues reported cardioprotection in an in vivo mouse heart model of
ischemia/reperfusion when ilomasat was administered intravenously at 6 µmol/kg upon
releasing coronary occlusion [37]. However, the percentage of in situ MMP-2 inhibition was
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not determined in the abovementioned studies and in the latter study, authors did not examine
directly the MMP inhibitory effect of ilomastat.
Taken together, ilomastat at doses with moderate MMP-2 inhibition protects
cardiomyocytes thereby reducing infarct size when administered either before the onset of
ischemia or before the onset of reperfusion in vivo. Our results show that a moderate MMP-2
inhibition is sufficient for cardioprotection.
6.2 Study 2: the NO donor SNAP has cytoprotective effect on mESC-
derived cardiomyocytes
In study 2 we established an embryonic stem cell-derived cardiac myocyte-based in
vitro drug screening system and showed that the NO-donor SNAP was protective against
SI/R-induced cell death. Either a selective inhibitor of PKG or a non-selective inhibitor of
KATP channels interfered with this protection. In contrast to SNAP, the particulate guanylate
cyclase stimulator BNP had no effect on cell viability during SI. This is the first
demonstration that mESC-derived cardiomyocytes are a useful tool for screening
cytoprotective agents and their cytoprotective signaling pathways against simulated
ischemia/reoxygenation injury.
Currently used cell-based assays using primary neonatal cardiomyocytes have
limitations for screening cardioprotective agents, including variability introduced by the
isolation procedure and limited proliferation [80]. Adult cardiomyocytes are suitable to study
individual cells, especially their electrophysiological properties. However, extracellular
matrix proteins are required for their maintenance which may influence viability during SI
[81]. The H9c2 cardiomyoblast cell line is a widely used model for in vitro drug screening as
well. However, H9c2 cells differ from primary cardiomyocytes, because of lacking
spontaneous electric activity and clearly developed sarcomeric structures [82]. Therefore,
advantages of ESC-based assays are the well-reproducible production of contracting
myocardial cells and that they do not require sacrificing high number of animals.
Therefore, here we validated a mESC-derived cardiomyocyte-based drug-screening platform
using the NO donor SNAP. SNAP is a well-known cardioprotective compound. It exerts both
early and late preconditioning-like cardioprotective effect in various models [83,84] and
attenuates apoptosis in neonatal cardiomyocytes [85]. Accordingly, in the present study,
SNAP showed a concentration-dependent increase in viability of mESC-derived
cardiomyocytes after SI/R insult. This finding indicates that mESC-derived cardiomyocytes
are useful tools for testing cardioprotective agents and suggests that NO donors may also be
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cytoprotective for stem cell-derived cardiomyocytes implanted into ischemic areas of the
myocardium. Moreover NO has also been shown to promote cardiac-committed
differentiation of mESCs [86].
It has been well established that NO donors including SNAP exert protective effect
against myocardial ischemia/reperfusion injury via activation of soluble guanylate cyclase and
increased cGMP signaling (for a review see ref. 87). We have recently shown that SNAP
induces cytoprotection via the activation of soluble guanylate cyclase in neonatal
cardiomyocytes [58]. However, in our previous studies the efficacy of SNAP-induced
cytoprotection was more pronounced in neonatal cardiomyocytes than shown here in mESC-
derived cardiomyocytes. This difference is probably due to the low expression level of soluble
guanylate cyclase and nitric oxide synthase (NOS) at 6-8 days old stage of mESC-derived
cardiomyocytes [88]. The latter is in accordance with our present results that the NOS
inhibitor L-NNA did not affect cell viability after SI/R injury of mESC-derived
cardiomyocytes showing that endogenous NO is not involved in cardiocytoprotection.
To test if activation of particulate guanylate cyclase can increase cell viability similar to
SNAP, the effect of BNP was tested. BNP is a potent cardioprotective peptide, as it is able to
reduce infarct size in rat heart preparations [71] and to protect neonatal rat cardiomyocytes
against SI/R injury [58]. Interestingly, in our present study, cell viability was not influenced
by either concentration of BNP in mESC-derived cardiomyocytes. This finding may be due to
a low expression of the BNP specific NPR-A receptor during mouse ESC differentiation [89].
We further identified cardioprotective signaling pathways downstream of cGMP in
mESC-derived cardiomyocytes. In the cardiomyocytes, at least three classes of protein targets
are activated by cGMP, including cGMP-dependent PKG, cGMP-regulated
phosphodiesterases, and cyclic nucleotide-gated ion channels [60], In the present study, the
involvement of PKG in SNAP-induced protection was tested by the PKG inhibitor KT-5823
during SI, which interferes with PKG at the level of the ATP binding site of its catalytic
domain KT-5823 alone did not affect the viability of mESC-derived cardiomyocyte, but
interfered with the cytoprotective effect of SNAP, which suggests that the mechanism of
SNAP-induced protection involves PKG. Our present findings in mESC-derived
cardiomyocytes are consistent with our previous results obtained in neonatal rat
cardiomyocytes, in which the PKG inhibitor abolished the protective effect of SNAP [58].
However, it is of interest that Mobley et al. showed that PKG was down-regulated during
cardiomyocyte differentiation and inhibition of PKG facilitated cardiac-committed
differentiation of mESCs [90].
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Xu et al. demonstrated that exogenous NO mediates the production of reactive oxygen
species and may act via the activation of cGMP/PKG signaling, triggering
cardiocytoprotection by mitochondrial KATP channel opening or by opening the mitochondrial
permeability transition pore in adult rat cardiomyocytes KATP channels have a prominent role
in the electrical excitability of cardiac-committed mESC-derived cells [91]. Therefore, in the
present study, we investigated the involvement of KATP channels in SNAP-induced
cytoprotection in mESC-derived cardiomyocytes. The nonselective KATP channel inhibitor
glibenclamide alone did not affect mESC-derived cardiomyocyte viability, but abolished the
cytoprotective effect of SNAP. This is in line with several earlier reports in other systems
[92,93].
Taken together, our present study is the first demonstration that mESC-derived
cardiomyocytes exposed to SI/R injury are a useful alternative tool for in vitro screening of
potential cardioprotective agents and to study their downstream cellular signaling pathways.
The major advantages of ESC-based screening platforms over other cellular assays are the
well reproducible production of beating myocardial cells and that it does not require to
sacrifice a number of animals. All the above-mentioned findings emphasize the necessity of
detailed analyses of signal transduction pathways in ESC-derived cells both in physiological
and pathological conditions to establish well-reproducible ESC-derived drug screening
platforms and to predict the viability of these cells after implantation into an ischemic region
of a tissue.
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7. CONCLUSIONS AND FURTHER PERSPECTIVES
Study 1 is the first demonstration that
 the cardioprotective effect of ilomastat occurs via the moderate inhibition of MMP-2.
 ilomastat has direct cytoprotective effect via attenuating the intracellularly active
MMP-2 activity as proved by in situ zymography. This finding was proven by the
previously established drug screening platform that is suitable for testing
cardioprotective compounds.
 ilomastat reduced infarct size when administered either before the onset of ischemia
or before the onset of reperfusion in vivo. However, the cardioprotective doses of
ilomastat are not overlapped, when administered before ischemia or before
reperfusion.
We conclude that MMP-2 inhibition before the onset of reperfusion is a promising target
in the treatment of AMI, since it may have high clinical relevance during recanalization
therapy via percutaneous coronary intervention. Furthermore, moderate inhibition of MMP-2
might be a useful tool to reduce infarct size and improve clinical outcomes of AMI in patients
without the occurrence of severe side effects derived from high efficacy MMP inhibition.
In Study 2, we demonstrated for the firs time that
 the NO-donor SNAP is protective against SI/R-induced cell death of mESC-derived
cardiomyocytes. Moreover, we proved that the activation of cGMP-PKG signaling
cascade is involved in this protection.
 mESC-derived cardiomyocytes exposed to SI/R injury can be a useful tool for
predicting the viability of ESC-derived cardiomyocytes after implantation into the
ischemic myocardium.
 this mESC-derived cardiomyocyte-based platform can be used for in vitro testing of
potential cardioprotective drugs and to study their downstream signaling pathways.
In conclusion, stem-cell-derived cardiomyocytes may be a useful source for cardiac repair
after AMI. The major limitation that needs to be overcome towards clinical translation is the
low survival rate of cells after implantation. Therefore, the improvement of cell replacement
therapy is one of the most important aims of our further investigations.
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Pharmacological  inhibition  of  matrix  metalloproteinase-2  (MMP-2)  is a promising  target  for  acute  car-
dioprotection  against  ischemia/reperfusion  injury.  Therefore,  here  we  investigated  if the  MMP  inhibitor
ilomastat  administered  either  before  ischemia  or before  reperfusion  is  able  to  reduce  infarct  size via
inhibition  of  MMP-2,  the  most  abundant  MMP  in  the  rat  heart.
Infarct-size  limiting  effect  of  ilomastat  (0.3–6.0  mol/kg)  was  tested  in  an  in  vivo  rat  model  of
myocardial  infarction  induced  by  30  min  coronary  occlusion/120  min  reperfusion.  Ilomastat  at  0.75  and
1.5  mol/kg  decreased  infarct  size  signiﬁcantly  as compared  to the  vehicle-treated  (dimethyl  sulfox-
ide)  group  (from  66.1 ± 4.6%  to 45.3 ±  7.0%  and  46.7  ±  5.5%  of area  at risk,  p  < 0.0.5,  respectively),  when
administered  5 min  before  the  onset  of  ischemia.  Ilomastat  at 6.0 mol/kg  signiﬁcantly  reduced  infarct
size  from  its  control  value  of  65.4  ± 2.5% to 52.8  ±  3.7%  of area  at risk  (p <  0.05),  when  administered  5 min
before  the onset  of reperfusion.  Area  at risk  was  not  signiﬁcantly  affected  by  ilomastat  treatments.  To
further  assess  the  cytoprotective  effect  of ilomastat,  primary  cardiomyocytes  isolated  from  neonatal
rats  were  subjected  to  240 min  simulated  ischemia  followed  by 120  min  simulated  reperfusion  in  the
presence  of  ilomastat  (5  nM–5  M).  Ilomastat  at 500  nM  and  5 M signiﬁcantly  increased  cell viability
when  compared  to vehicle  treated  group.  To  assess  the  in  situ MMP-2  inhibitory  effect  of  ilomastat,  in
separate  experiments  in  situ zymography  was performed  in  cardiomyocytes.  The  cytoprotective  con-
centration  of ilomastat  (500  nM)  showed  a moderate  (approximately  25%)  inhibition  of intracellular
MMP-2  in  ischemic/reperfused  cardiomyocytes.  In  these  cells,  MMP-2  immunostaining  showed  a  90%
colocalization  with  the  in  situ  gelatinolytic  activity.
We  conclude  that  the  MMP  inhibitor  ilomastat  reduces  infarct  size  when  administered  either  before  the
onset of ischemia  or before  the onset  of reperfusion  in  vivo.  Furthermore,  this  is the  ﬁrst  demonstration
that  a moderate  inhibition  of  intracellular  MMP-2  is  sufﬁcient  to confer  cardiocytoprotection.
© 2013 Elsevier Ltd. All rights reserved.
1. Introduction
Acute myocardial infarction and its complications are the lead-
ing cause of death in the industrialized countries. The treatment of
acute ischemic heart disease has entered a new era through early
reperfusion therapy, however, irreversible cell injury leading to
Abbreviations: DMSO, dimethyl sulfoxide; ILO, ilomastat; LAD, left anterior
descending coronary artery; MMP,  matrix metalloproteinase; PBS, phosphate buffer
solution; PI, propidium iodine.
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E-mail address: peter.ferdinandy@pharmahungary.com (P. Ferdinandy).
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apoptosis and necrosis may  be precipitated by reperfusion, which
may  contribute to the development of infarction [1,2]. Therefore,
to protect the heart from acute ischemic and reperfusion injury, i.e.
to reduce infarct size is of great clinical relevance.
The pathomechanism of myocardial ischemia and reper-
fusion injury is not completely revealed. Since the original
observation by the research group of Richard Schulz, the involve-
ment of matrix metalloproteinases (MMP)  in acute myocardial
ischemia/reperfusion injury has been well-established [3–9].
MMPs  are zinc dependent, neutral endopeptidases involved in sev-
eral physiological processes, such as embryogenesis, angiogenesis
and re-building of extracellular matrix (ECM). Gelatinase types of
MMPs, MMP-2 and -9, are implicated in numerous cardiovascu-
lar diseases including ischemia/reperfusion injury [10]. Recently,
the presence of MMP-2 has been shown in the cytosol of intact
1043-6618/$ – see front matter ©  2013 Elsevier Ltd. All rights reserved.
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cardiomyocytes [11]. Moreover, several cardiac contractile pro-
teins, such as titin and troponins, were shown to be poten-
tial targets of acute intracellular MMP-2 activation during
ischemia/reperfusion [12]. Therefore, MMP-2 became a major tar-
get for drug development in acute cardiovascular pathologies
including myocardial infarction [13,14].
We have previously reported that MMP-2 activity was  mod-
erately decreased during ischemic preconditioning [6] and that
exogenous inhibition of MMPs  by ilomastat, a non-selective MMP
inhibitor, diminished ischemia-induced MMP-2 activity in isolated
rat hearts [5]. Furthermore, we have described that the activ-
ities of MMP-2 and MMP-9 were decreased signiﬁcantly in an
in vivo rat model of ischemic late preconditioning [3]. Moreover,
we and others have shown that ilomastat reduces infarct size in
rats and mice ([3,15], for review see Refs. [10,16]). Nevertheless,
the dose–response relationships of ilomastat administered before
the onset of ischemia as well as before the onset of reperfusion are
still unknown. Moreover, there is no proof if ilomastat-induced car-
dioprotection is due to MMP-2 inhibition. Furthermore, it is also not
known, what extent of intracellular MMP-2 inhibition is needed for
effective cardioprotection.
Therefore, in the present study, we aimed to investigate the
dose–response relationships of ilomastat administered before the
onset of ischemia as well as before the onset of reperfusion in an
in vivo rat model of myocardial infarction. Furthermore, to test if
ilomastat-induced cardioprotection is due to (and what extent of)
MMP-2 inhibition, we performed gelatin zymography and in situ
zymography followed by immunostaining of MMP-2 in cardiomy-
ocytes subjected to simulated ischemia/reperfusion.
2. Materials and methods
2.1. Animals
Animal handling and the investigation was in conjunction with
Guide for the Care and Use of Laboratory Animals published by
the U.S. National Institutes of Health (National Institutes of Health
publication 85-23, revised 1996), and it was approved by a local
animal ethics committee.
Male Wistar rats (Charles-River, Germany) weighing 280–370 g
were used in the experiments housed in individually ventilated
cages. Animals were fed with standard murine chow and unlimited
access to water was ensured prior to the surgical intervention. For
the cell culture experiments, neonatal Wistar rats were purchased
from the local live-stock of the University of Szeged.
2.2. In vivo studies
2.2.1. Surgical procedure of coronary occlusion
Rats were anesthetized by intraperitoneal injection of 60 mg/kg
sodium pentobarbital (Euthasol, Produlab Pharma b.v., Raams-
donksveer, The Netherlands). Animals were mechanically venti-
lated (Model 683, Harvard Apparatus, Holliston, MA) with room
air in a volume of 6.2 ml/kg and a frequency of 55 ± 5 breath/min
according to body weight. Rats were placed in supine position
on a heating pad to maintain body core temperature in physio-
logical range (37.0 ± 1.0 ◦C). Right carotid artery was  cannulated
to measure mean arterial blood pressure by a pressure trans-
ducer (Experimetria Inc., Budapest, Hungary). Mean arterial blood
pressure and body surface electrocardiogram (ECG) was  moni-
tored throughout the experiments (Haemosys, Experimetria Inc.,
Budapest, Hungary). Right jugular vein was also cannulated for
ﬂuid substitution and drug administration. Left anterior descending
coronary artery (LAD) occlusion was induced by left thoraco-
tomy. A 5-0 Prolene suture (Ethicon, Johnson & Johnson, Budapest,
Fig. 1. Panel A: In vivo experimental protocol: rats were subjected to 30 min
ischemia/120 min  reperfusion to measure infarct size. Ilomastat at 0.3, 0.75, 1.5
and 3.0 mol/kg or vehicle (DMSO) was administered intravenously (upward closed
arrow) at 5 min  before the onset of ischemia. To maintain serum level of ilomastat,
repeated boluses with half dose of the ﬁrst bolus were administered in every 15 min,
three times: at the 10th and 25th min  of ischemia and at the 10th min of reperfusion
(upward open arrows). Panel B: Effect of ilomastat treatment on infarct size when
administered before ischemia. *p < 0.05 compared to vehicle-treated group, n = 7–8,
data are shown as mean ± S.E.M.
Hungary) was  placed around LAD artery and a small plastic knob,
which was  threaded through the ligature and placed in contact with
the heart, was  used for making occlusion for 30 min. Appearance
of ischemia was conﬁrmed by ST segment elevation and arrhyth-
mias. After 30-min ischemia, hearts were reperfused for 120 min
by releasing the ligature. Restoration of blood ﬂow was conﬁrmed
by arrhythmias observed in the ﬁrst minutes of reperfusion.
2.2.2. Experimental groups
In ﬁrst series of in vivo experiments, ilomastat was  administered
before the onset and during the 30-min ischemia. Animals were
divided into ﬁve groups. Dimethyl sulfoxide (DMSO; 11.6 w/v%
solution diluted with physiological saline) as vehicle or 0.3, 0.75,
1.5, and 3.0 mol/kg ilomastat were administered intravenously in
slow bolus 5 min  before ischemia (Fig. 1A). To maintain serum level
of ilomastat, additional 3 boluses of vehicle (5.8 w/v% DMSO solu-
tion) or ilomastat with half dose (0.15, 0.375, 0.75; and 1.5 mol/kg,
respectively), were given at the 10th, 25th min  of ischemia and at
the 10th min of reperfusion. We  estimated the maintaining doses of
ilomastat according to its half-life based on pharmacokinetic data
described previously in rodents after a single intravenous bolus
injection [17].
In the second series of in vivo experiments DMSO (11.6 w/v%
solution) or ilomastat (0.75, 1.5, 3.0, and 6.0 mol/kg) bolus was
injected at the 25th min  of ischemia. Maintaining boluses (5.8 w/v%
DMSO or 0.375, 0.75, 1.5, and 3.0 mol/kg, respectively) were
administered at the 10th, 25th and 40th min  of reperfusion (Fig. 2A)
to maintain constant ilomastat concentration in blood during the
early phase of reperfusion.
2.2.3. Determination of infarct size
After 120 min  of reperfusion hearts were isolated for infarct size
measurements. Hearts were perfused in Langendorff perfusion sys-
tem with 37 ◦C Krebs–Henseleit buffer (composition given in Ref.
[18]) to remove blood from the coronary vessels. After 5 min  of
perfusion, risk area was re-occluded, and hearts were perfused
with 4 ml  of 0.1% Evans blue dye through the ascending aorta.
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Fig. 2. Panel A: In vivo experimental protocol: rats were subjected to 30 min
ischemia/120 min  reperfusion to measure infarct size. Ilomastat at 0.75, 1.5, 3.0,
and  6.0 mol/kg or vehicle (DMSO) was administered intravenously (upward closed
arrow) at 5 min  before the onset of reperfusion. To maintain serum level of iloma-
stat, repeated boluses with half dose of the ﬁrst bolus were administered in every
15 min, three times: at the 10th, 25th and the 40th min  of reperfusion (upward
open arrows). Panel B: Effect of ilomastat treatment on infarct size when adminis-
tered before reperfusion. *p < 0.05 compared to vehicle-treated group, n = 7–8, data
are shown as mean ± S.E.M.
Following Evans staining, hearts were cut into 5 transversal slices
and incubated in 1% triphenyl-tetrazolium-chloride for 10 min  at
37 ◦C followed by formalin ﬁxation for 10 min. Planimetric evalu-
ation was carried out to determine infarct size using InfarctSizeTM
software, (Pharmahungary, Szeged, Hungary; [19]).
2.3. In vitro studies
2.3.1. Inhibition of gelatinase activity by ilomastat
To determine the source of the gelatinolytic activity and its
inhibition by ilomastat, gelatin zymography was performed on car-
diac tissue homogenate of a non-treated control rat. Gelatinolytic
activities of MMP-2 were examined as previously described in
detail [20]. Brieﬂy, 8% polyacrylamide gels were copolymerized
with gelatin (2 mg/ml, type A from porcine skin, Sigma–Aldrich,
Budapest, Hungary), and 50 g of protein per lane was  loaded. After
electrophoresis (90 V, 1.5 h), gels were washed ﬁrstly with renatu-
ration buffer (Bio-Rad, Hercules, CA; containing 2.5% Triton X-100)
for 3× 15 min  then incubated in development buffer (Bio-Rad, Her-
cules, CA) for 20 min  to eliminate Triton-X-100. Gels were sliced
according to the lanes and the slices were incubated separately
for 20 h at 37 ◦C at pH 7.4 in development buffer in the presence
of vehicle and/or different concentrations of ilomastat (0.5 nM and
5.0 nM). Recombinant, human MMP-2 was used as positive control.
Gels were then stained with 0.05% Coomassie brilliant blue (G-250,
Sigma–Aldrich, Budapest, Hungary). Gelatinolytic activities were
detected as transparent bands against the dark-blue background.
Band intensities were quantiﬁed (Quantity One software, Bio-Rad,
Hercules, CA) and expressed in arbitrary units. The gelatin zymog-
raphy protocol does not contain any component or step, which may
inhibit proteases including other MMPs.
2.3.2. Simulated ischemia/reperfusion in cardiomyocytes
Neonatal rat cardiomyocytes were cultured in 48-well plates.
Neonatal cardiomyocytes were chosen for the present study, as
they can be harvested on culture dishes without coating. The lack
of coating is important in the present study, as coating materials
(e.g. laminin, collagen, etc.) could inﬂuence the action of matrix
metalloproteinases [21,22]. Cell isolation and culturing method
was described previously in detail [23,24]. Brieﬂy, neonatal rats
were sacriﬁced by cervical dislocation and hearts were placed
into ice cold PBS solution. Ventricles were digested in 0.25%
trypsin (Invitrogen, Life Technologies Hungary Ltd., Budapest,
Hungary) solution and cell suspension was centrifuged at 400 × g,
for 15 min  at 4 ◦C. Cell pellet was re-suspended in Dulbecco’s
Modiﬁed Eagle Medium (Sigma–Aldrich, Budapest, Hungary)
supplemented with l-glutamine (Sigma–Aldrich, Budapest,
Hungary), Antibiotic–antimycotic solution (Sigma–Aldrich,
Budapest, Hungary) and 10% fetal bovine serum (Gibco, Life Tech-
nologies Hungary Ltd., Budapest, Hungary). Cells were counted
in a hemocytometer, and seeded into 48-well plates at a density
of 5 × 104 cell/well. After 24 h, the growth medium was replaced
with differentiation medium containing 1% fetal bovine serum.
Cardiomyocytes were kept under normoxic conditions (37 ◦C, in
95% air and 5% CO2 gas mixture) for three days prior to simu-
lated ischemia/reperfusion experiments. We  used a combination of
hypoxic chamber and hypoxic solution to simulate tissue ischemia.
In the simulated ischemic group, the medium of the cultures were
replaced with a hypoxic solution (composition given in Ref. [25])
and plates were kept in a hypoxic chamber (gassed with 95% N2
and 5% CO2 at 37 ◦C) for 240 min  in the presence or absence of
ilomastat (5 nM,  50 nM,  500 nM and 5 M).  The vehicle group was
treated with 0.2% DMSO. During simulated reperfusion cells were
covered with differentiation medium (containing 1% fetal bovine
serum) and kept in a normoxic incubator for 120 min.
2.3.3. Cell viability assay
Cell viability was assessed by a calcein and propidium iodine
(PI) assay performed in each group after 2 h simulated reperfusion
[26]. Brieﬂy, the growth medium was removed, cells were washed
with PBS twice and incubated with calcein (1 M)  for 30 min.
Then calcein solution was replaced with fresh PBS and ﬂuores-
cence intensity of each well was  detected by ﬂuorescent plate
reader (FluoStar Optima, BMG  Labtech, Auro-Science Consulting
Ltd., Budapest, Hungary). Then PI (50 M)  and digitonin (100 M)
(Sigma–Aldrich, St. Louis, MO)  were added to PBS and cells were
incubated for 7 min. Then PI solution was  replaced with fresh PBS
and ﬂuorescent intensity was  detected with same settings.
2.3.4. In situ zymography and MMP-2 co-localization
To detect in situ MMP-2 activity, neonatal rat cardiomyocytes
were cultured in 24-well tissue culture plate at the density of
105 cells/well for 3 days. The medium of cells was  replaced with
hypoxic solution supplemented with DQTM gelatin (Invitrogen,
Life Technologies Hungary Ltd., Budapest, Hungary) at 40 g/ml
concentration. Cells were then subjected to 240 min  simulated
ischemia in the presence of ilomastat (at 500 nM concentration) or
its vehicle. Other series of cells were covered with normoxic solu-
tion and kept in normoxic incubator for 240 min. Subsequently, all
groups were subjected to reoxygenation: the hypoxic, or normoxic
solution of the cells was  replaced with differentiation medium sup-
plemented with DQ gelatin and cells were placed into a normoxic
incubator for 120 min. Finally cells were washed with PBS, and
ﬁxed in 3.7% paraformaldehyde dissolved in PBS for 15 min. MMP-
2 ﬂuorescent immunostaining using anti-proMMP-2 antibody
(Chemicon, MAB3308; Merck Ltd., Budapest, Hungary; secondary
antibody: rhodamine-labeled goat anti-mouse antibody; Abcam,
AB5885, Cambridge, UK) was  assessed to detect co-localization
of MMP-2 with gelatinolytic activity. Nuclei of the cells were
stained with Hoechst 33342 (Invitrogen, Life Technologies Hungary
Ltd., Budapest, Hungary). After the subsequent washing steps,
cells were covered with ﬂuorescent mounting medium (Dako,
Frank Diagnosztika Ltd., Budapest, Hungary), and ﬂuorescence was
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Fig. 3. Representative images of MMP-2 activity in gelatin zymograms in the pres-
ence of 0, 0.5 and 5.0 nM ilomastat.
detected with a confocal laser microscope in sequential scanning
mode (Olympus Fluoview 1000, Olympus Hungary Ltd., Budapest,
Hungary). Assessment of the gelatinolytic activity was  carried out
by quantifying different parameters of ﬂuorescent particles from
10 ﬁelds selected randomly on each coverslip. Four coverslips were
analyzed in each group. The number, total area, and area fraction of
ﬂuorescent signal, and the analyses of co-localization were quan-
tiﬁed on images by ImageJ 1.45 software (National Institutes of
Health, Bethesda, MD).
2.4. Statistical analysis
Statistical analysis was performed using Sigmaplot 11.0 soft-
ware. All data were given as mean ± standard error of the mean
(S.E.M.). One-way analysis of variance followed by Fisher-LSD post
hoc tests were performed to show differences among groups. p val-
ues of ≤0.05 were accepted as statistically signiﬁcant difference
compared to vehicle control.
3. Results
3.1. Effect of ilomastat on infarct size in vivo
The cardioprotective effect of ilomastat administered before
the onset of ischemia (Fig. 1) or before the onset of reperfusion
(Fig. 2) was studied in an in vivo myocardial infarction model
induced by coronary occlusion in rats. When administered before
the onset of ischemia, ilomastat at 0.75 and 1.5 mol/kg doses
reduced infarct size signiﬁcantly as compared to vehicle-treated
group (from 66.1 ± 4.6% to 45.3 ± 7.0% and 46.7 ± 5.5% of area at
risk, respectively) showing a U-shaped dose–response relation-
ship (Fig. 1B). When administered before the onset of reperfusion,
ilomastat at 6.0 mol/kg reduced infarct size signiﬁcantly (from
65.4 ± 2.5% to 52.8 ± 3.7% of area at risk), however, lower doses
were ineffective (Fig. 2B). There was no signiﬁcant difference in the
area at risk among the groups (data not shown). There was no signif-
icant difference in the mean arterial blood pressure and heart rate
among the groups (Tables 1 and 2 are shown in data supplement).
3.2. Effect of ilomastat on cardiac gelatinolytic activity
In a preliminary series of studies, the in vitro MMP-inhibitory
dose range of ilomastat was estimated in rat cardiac tissue
homogenate by gelatin zymography. We  have found that the IC50 of
ilomastat was 0.83 nM.  Gelatinolytic activity was detectable only at
72 kDa in cardiac homogenate suggesting that only MMP-2 activity
was present in the heart tissue at a signiﬁcant level (Fig. 3).
3.3. Effect of ilomastat on ischemia/reperfused cardiomyocytes
In order to test if a direct cardiocytoprotection by MMP-
2 inhibition of ilomastat is involved in its cardioprotective
Fig. 4. Panel A: Experimental protocol of cell culture studies. Simulated
ischemia/reperfusion was  induced in the presence of vehicle (DMSO) or ilomastat.
Viability assays and in situ zymography were performed after the end of simulated
reperfusion. Normoxic time-matched control groups were kept under normoxic
solution in normoxic conditions. Panel B: Effect of ilomastat on cell viability in neona-
tal  rat cardiomyocytes after simulated ischemia/reperfusion. *p < 0.05 compared to
vehicle treated group, n = 6; data are shown as mean ± S.E.M.
effect, we  examined ilomastat-induced cytoprotection in isolated
neonatal rat cardiomyocytes subjected to normoxia or simulated
ischemia/reperfusion (Fig. 4A). Ilomastat at a dose range of 0.5 nM
up to 5 M did not inﬂuence cell viability in normoxic condi-
tions (Table 3, supplementary material). However, ilomastat at
500 nM and 5 M signiﬁcantly increased cell viability as compared
to vehicle treated group (from 8.6 ± 0.3 to 9.8 ± 0.4 and 9.7 ± 0.2,
respectively, expressed in arbitrary units of ﬂuorescent intensity)
in cardiomyocytes subjected to simulated ischemia/reperfusion
(Fig. 4B).
3.4. In situ MMP-2 inhibition by ilomastat in ischemia/reperfused
cardiomyocytes
To test the in situ MMP  inhibitory efﬁcacy of the cardiocy-
toprotective concentration of ilomastat, we  performed in situ
zymography on isolated rat cardiomyocytes subjected to simulated
ischemia/reperfusion (Fig. 5). Simulated ischemia/reperfusion
increased gelatinolytic activity signiﬁcantly from its control value
of 0.48 ± 0.04% to 0.93 ± 0.05% of area fraction. The cardiocytopro-
tective concentration of ilomastat (500 nM,  see Fig. 4B) moderately
inhibited the in situ gelatinolytic activity approximately by 25%,
i.e. from 0.93 ± 0.05% to 0.70 ± 0.04% of area fraction, during sim-
ulated ischemia/reperfusion (Fig. 5/D). Moreover, we performed
separate experiments to show co-localization of MMP-2 with the
ﬂuorescent gelatinolytic signal in isolated rat cardiomyocytes sub-
jected to simulated ischemia/reperfusion. MMP-2 showed over 90%
co-localization rate with gelatinolytic activity in all groups (Fig. 6).
4. Discussion
Here we  have demonstrated that ilomastat, a non-selective
MMP inhibitor, reduced infarct size when administered either
before the onset of ischemia or before the onset of reperfusion
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Fig. 5. Effect of the cardiocytoprotective concentration of ilomastat (500 nM)
on  in situ MMP-2 activity in neonatal rat cardiomyocytes subjected to sim-
ulated ischemia/reperfusion. Panel A–C:  Representative ﬂuorescent confocal
images from neonatal rat cardiomyocytes subjected to normoxia (A), simulated
ischemia/reperfusion (B), or simulated ischemia/reperfusion in the presence of
500 nM ilomastat (C). Green color represents MMP-2 activity as measured by
in  situ zymography FITC signal; blue color represents the nuclei of the cells.
Scale bars = 20 m.  Panel D shows area fraction of ﬂuorescent images. *p < 0.001
compared to normoxic vehicle-treated group, #p < 0.01 compared to simulated
ischemia/reperfusion, vehicle-treated group, n = 6; data are shown as mean ± S.E.M.
(For  interpretation of the references to color in this ﬁgure legend, the reader is
referred to the web  version of this article.)
in vivo and revealed its cardioprotective dose–response rela-
tionship. Moreover, we have shown that an approximately 25%
inhibition of intracellular MMP-2 activity by ilomastat confers sig-
niﬁcant cardiocytoprotection. This is the ﬁrst demonstration that
the cardioprotective effect of ilomastat may  involve a cardiocyto-
protective mechanism due to a moderate inhibition of MMP-2.
In our present study, ilomastat reduced infarct size dose-
dependently when administered either before ischemia or before
reperfusion. We have found a slightly different dose range between
the 2 administration patterns. When administered before the
onset of ischemia, the effective doses of ilomastat were 0.75 and
1.5 mol/kg, however, higher doses of ilomastat were not signif-
icantly effective. Nevertheless, when ilomastat was administered
before the onset of reperfusion, 6 mol/kg ilomastat was  found to
decrease infarct size, and lower doses were ineffective. This is the
ﬁrst demonstration that the cardioprotective dose ranges of ilomas-
tat, when administered before ischemia or before reperfusion, were
not overlapping in vivo. Our present results are supported by previ-
ous studies describing that Zn2+-binding type MMP  inhibitors, such
as doxycycline and o-phenantroline, improved cardiac mechani-
cal function after ischemia/reperfusion injury via the inhibition of
MMP-2 in isolated rat hearts [4,27,28]. We  have previously shown
that iv. injection of 1.5 mol/kg ilomastat before a 30-min ischemia
decreased infarct size comparable to ischemic late precondition-
ing in an in vivo rat model of coronary occlusion [3]. Recently,
Bell and colleagues reported cardioprotection in a mouse model of
ischemia/reperfusion when administered iv. 6 mol/kg ilomastat
at the release of coronary occlusion [15]. However, in the above-
mentioned studies the percentage of in situ MMP-2 inhibition was
not determined and in the latter study, authors did not examine
directly the MMP  inhibitory effect of ilomastat.
Ilomastat is a non-selective MMP  inhibitor, therefore, the ques-
tion has arose, inhibition of which MMP  isoenzyme was  responsible
for the cardioprotective effect of ilomastat. To answer this question,
here we  performed gelatin zymography from cardiac homogenates
isolated from untreated rats and used puriﬁed MMP-2 enzyme to
identify the MMP-2 speciﬁc activity in the zymogram. Gelatinolytic
activities at 72 and 64 kDa were detectable according to the molec-
ular weights of the two  active isoforms of MMP-2. Bands of other
molecular weights were not present on the zymogram. Further-
more, here we  proved that gelatinolytic activity was co-localized
with MMP-2 protein in cardiomyocytes. These results show that
gelatinolytic activity in the heart is derived solely from MMP-2
Fig. 6. Representative immunoﬂuorescent confocal images from cultured cardiomyocytes subjected to normoxia or simulated ischemia/reperfusion in the presence or
absence of ilomastat, respectively. Green ﬂuorescence: ﬂuorescent signal of gelatin substrate after proteolytic cleavage. Red ﬂuorescence: MMP-2 immunostaining, blue
ﬂuorescence: cell nuclei. Scale bars = 20 m.  (For interpretation of the references to color in this ﬁgure legend, the reader is referred to the web version of this article.)
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activity. Accordingly, we have previously shown that MMP-2 activ-
ity can be detected both in intact and in ischemia/reperfused rat
ventricular samples [5], thus, MMP-2 is suspected to be the only
MMP  isoform with gelatinolytic activity in the rat myocardium. This
is in accordance with previous ﬁndings by others, who have shown
that MMP-2 possesses a predominant expression in both animal
and human cardiomyocytes and cardiac tissue [29,30]. Neverthe-
less, it cannot be excluded that inhibition of other non-gelatinolytic
proteases may  be involved in the cardiocytoprotective effect of
ilomastat.
Here we further tested the magnitude of MMP-2 inhibition
necessary for cardioprotection and found that the cardiocyto-
protective dose of ilomastat inhibited MMP-2 activity only by
25%. Our previous ﬁndings showing that cardioprotection by late
ischemic preconditioning reduced MMP-2 activity by approxi-
mately 20% strongly supports our present results [3]. Our present
study suggests that a moderate MMP-2 inhibition is sufﬁcient
for cardioprotection. Due to the well-known side effects of
MMP inhibitors including tendonitis-like ﬁbromyalgia and mus-
culoskeletal syndrome (for review see Ref. [14,31]), it is of great
clinical importance that possibly there is no need for high efﬁcacy
MMP inhibitors to protect the heart against ischemia/reperfusion
injury.
The cardioprotective cellular mechanism in which MMP-2
inhibition might be involved is not known and has not been
investigated in the present study. Although endogenous cardio-
protection by early and late ischemic preconditioning as well as
postconditioning involve an MMP-2 inhibition-dependent mech-
anism [3,5,6,32] the exact mechanism by which MMP  inhibition
results in cardioprotection is not known. Bell et al. reported that
ilomastat protects the heart against reperfusion injury indepen-
dently from the well-known cardioprotective Reperfusion Injury
Salvage Kinase/mitochondrial permeability transition pore open-
ing pathways [15]. Recently, a large number of studies focused
on the intracellular actions of MMP-2, which can degrade several
newly identiﬁed intracellular targets including troponin I, myosin
light chain-1, -actinin (for review see Ref. [11]) and titin [12]. The
degradation of myocardial contractile proteins may  contribute to
the induction of proapoptotic signals in cardiomyocytes and thus
leads to cell death and contractile dysfunction (for review see Ref.
[33]).
We  conclude that ilomastat at doses with moderate MMP-2 inhi-
bition protects cardiomyocytes thereby reducing infarct size when
administered either before the onset of ischemia or before the onset
of reperfusion in vivo. Our results show that a moderate MMP-2
inhibition is sufﬁcient for cardioprotection.
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Abstract Embryonic stem cell (ESC)-derived cardiomyo-
cytes are a promising cell source for the screening for
potential cytoprotective molecules against ischemia/reperfu-
sion injury, however, little is known on their behavior in
hypoxia/reoxygenation conditions. Here we tested the cyto-
protective effect of the NO-donor SNAP and its downstream
cellular pathway. Mouse ESC-derived cardiomyocytes were
subjected to 150-min simulated ischemia (SI) followed by
120-min reoxygenation or corresponding non-ischemic
conditions. The following treatments were applied during SI
or normoxia: the NO-donor S-Nitroso-N-acetyl-D,L-penicil-
lamine (SNAP), the protein kinase G (PKG) inhibitor, the
KATP channel blocker glibenclamide, the particulate guany-
late cyclase activator brain type natriuretic peptide (BNP),
and a non-specific NO synthase inhibitor (N-Nitro-L-arginine,
L-NNA) alone or in different combinations. Viability of cells
was assayed by propidium iodide staining. SNAP attenuated
SI-induced cell death in a concentration-dependent manner,
and this protection was attenuated by inhibition of either PKG
or KATP channels. However, SI-induced cell death was not
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affected by BNP or by L-NNA. We conclude that SNAP
protects mESC-derived cardiomyocytes against SI/R injury
and that soluble guanylate-cyclase, PKG, and KATP channels
play a role in the downstream pathway of SNAP-induced
cytoprotection. The present mESC-derived cardiomyocyte-
based screening platform is a useful tool for discovery of
cytoprotective molecules.
Keywords Stem cell  Nitric oxide  Ischemia/
reoxygenation  Signal-transduction 
Cardioprotection
Introduction
Ischemic heart disease is the leading cause of death in the
industrialized world, therefore, development of cardiopro-
tective therapies are of great importance.
In vitro cardiac myocyte-based drug screening platforms at
the early stage of the development of cardioprotective agents
are widely used. However, currently used assays based on
cardiomyoblast cell lines (H9c2) as well as primary neonatal
and adult cardiac myocytes [1] have limitations including
limited proliferation capacity, uncontrolled stress during cell
isolation and dissociation of cultured cells, low-throughput
nature, and poor predictability of the assays toward in vivo
efficacy [2]. Embryonic stem cells (ESC) are capable of
unlimited proliferation in vitro and differentiation into cardiac
myocytes [3], therefore, ESCs provide a promising source of
cardiac myocytes for in vitro drug screening [4, 5]. ESCs may
also become tools for regeneration therapy [6], however, sev-
eral limitations were reported including ethical, immunologi-
cal, and tumorigenicity problems, which restrict their clinical
application [7]. Moreover, transplanted cells undergo a signif-
icant rate of cell death shortly after transplantation, approaching
90 % within the first 24-h after transplantation [8]. One reason
is may be the unfavorable microenvironment grafted cells face
when injected into host cardiac muscle. In most studies, well-
nourished and oxygenated stem cells are transplanted into
poorly perfused tissue, where they are exposed to increased
oxidative stress and local inflammation [9]. Characterization of
these cells in a high throughput ischemia/reoxygenation test
system would be important, since little is known about the
ischemic tolerance and signal transduction pathways involved
in protection of ESC-derived cardiomyocytes.
It has been previously shown that nitric oxide (NO) has a
direct cytoprotective effect in case of simulated ischemia (SI) in
cardiomyocytes [10]. Furthermore, administration of the NO-
donor S-Nitroso-N-acetyl-D,L-penicillamine (SNAP, 2 mM)
has been shown to mimic preconditioning protection in mouse
hearts [11]. NO-mediated cytoprotection may act via different
signaling pathways. Intracellular elevation of cyclic guanosine
monophosphate (cGMP) by NO or natriuretic peptides has been
proposed to influence cellular responses to ischemia and to
contribute to cardioprotection. However, the contribution of
NO and its downstream signaling pathway in the protection of
ESC-derived cardiomyocytes has not been studied yet. Open-
ing of sarcolemmal and mitochondrial ATP-sensitive potas-
sium (KATP) channels can be activated by exogenous NO and
these channels have been demonstrated to mediate cardiopro-
tection [12]. However, the importance of this pathway in mouse
ESC (mESC)-derived cardiomyocytes is not known.
The aim of the present study was to test an mESC-derived
cardiomyocyte-based drug screening platform by investigating
whether the cytoprotective NO-donor SNAP is able to protect
these cells against SI/reoxygenation injury. We also investigated
the downstream pathways of the protection in this platform.
Methods
Mouse ESC Culture
Undifferentiated mESCs (Nkx2.5/EGFP transgenic C57BL/6
mouse ES cell line; TgNkx2.5/EGFP C57BL/6; passages 10–12)
were cultured on feeder layers of mitomycin C-inactivated
mouse embryonic fibroblasts (MEFs) which were obtained
from 13.5 days postcoitus mouse embryos, as described earlier
by Belteki [13]. mESCs were maintained in ES medium con-
sisting of Dulbecco’s Modified Eagle’s Medium (DMEM),
15 % (v/v) fetal bovine serum (FBS, Sera Laboratories Inter-
national, West Sussex, RH17 5PB, UK) supplemented with
1,000 U/mL mouse leukemia inhibitory factor (LIF, ESGRO,
Chemicon International, Budapest, Hungary), 0.1 mM non-
essential amino acids (NEAA), 0.1 mM b-mercaptoethanol
(b-ME), and 50 U/mL penicillin/50 lg/mL streptomycin.
mESCs were cultured on feeder layers for at least two passages
after thawing and subsequently were cultured without feeder
cells on 0.1 % gelatin-coated tissue culture plates in the pre-
sence of LIF (2,000 U/mL). Medium was changed daily for
standards maintenance. mESCs were usually passaged every
1–2 days prior reaching 70 % confluences.
Embryoid Body (EB) Formation and Cardiomyocyte
Differentiation
mESCs were dissociated from monolayer culture with
0.05 % trypsin–EDTA into a single cell suspension. EBs
were produced by the hanging drop (HD) method [14]; in
brief, mESCs were seeded as 4 9 104 cells/mL (resulting
in 800 cells/drop) suspension in differentiation medium
(regular DMEM without LIF). 2 days later, the EBs were
transferred and plated into 24-well plates on gelatin-coated
coverslips. 0.1 mg/mL ascorbic acid was supplemented to
induce cardiac differentiation. mESC-derived cardiomyo-
cytes were used at 6–8-day-old stage for SI/reoxygenation
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experiments. At this stage, the ratio of Nkx2.5-eGFP
positive cells, an early marker for cardiac differentiation,
exhibited 52.5 ± 10 % EGFP positivity (n = 30). The
cells were fluorescently imaged and analyzed by using
Digital Image Processing Software (AxioVision 4.8.1, Carl
Zeiss MicroImaging GmbH, Germany).
Experimental Groups
For cell viability experiments, mESC-derived cardiomyo-
cytes were tested under normoxic condition or were subjected
to SI (Fig. 1). The normoxic mESC-derived cardiomyocytes
were kept under normoxic conditions, i.e., the growth medium
was changed to a normoxic solution (in mM: NaCl 125, KCl
5.4, NaH2PO4 1.2, MgCl2 0.5, HEPES 20, glucose 15, taurine
5, CaCl2 1, creatine 2.5, BSA 0.1 %, pH 7.4, 310 mOsm/l)
[15] and the cells were incubated under 95 % air and 5 % CO2
at 37 C for 2.5 h. In the second series of experiments, mESC-
derived cardiomyocytes were subjected to SI by incubating
the cells in hypoxic solution (in mM: NaCl 119, KCl 5.4,
MgSO4 1.3, NaH2PO4 1.2, HEPES 5, MgCl2 0.5, CaCl2 0.9,
Na-lactate 20, BSA 0.1 %, 310 mOsm/l, pH = 6.4) [15] and
placing the plates in a humidified 37 C hypoxic chamber
exposed to a constant flow of a mixture of 95 % N2 and 5 %
CO2 for 2.5 h. The cells were then subjected to the following
treatments during SI or normoxic protocol: (1) untreated
control; (2) SNAP (10-7, 10-6, 10-5 M) (10) (Sigma, St.
Louis, MO, USA); (3) selective protein kinase G (PKG)
inhibitor KT-5823 (6 9 10-8 M), an effective concentration
that does not affect cell viability alone (10) (Sigma, St. Louis,
MO, USA); (4) SNAP (10-6 M, a concentration found here
protective) in combination with KT-5823 (6 9 10-8 M); (5)
brain type natriuretic peptide-32 (BNP, 10-9, 10-8, 10-7 M)
[16] (American Peptides, Sunnyvale, CA, USA); (6) nitric
oxide synthase (NOS) inhibitor N-Nitro-L-arginine (L-NNA,
10-4, 10-5 M) [17] (Sigma, St. Louis, MO, USA); (7) non-
selective KATP channel inhibitor glibenclamide (10
-6 M, an
effective KATP blocking concentration that does not affect
ischemia/reperfusion injury alone) [18] (Sigma, St. Louis,
MO, USA); (8) SNAP (10-6 M) and glibenclamide (10-6 M);
and dimethyl-sulfoxide (DMSO) (Sigma, St. Louis, MO,
USA) control groups.
Either normoxic or SI treatments were followed by 2 h
reoxygenation with growth medium without ascorbic acid
and superfusion with 95 % air and 5 % CO2 at 37 C.
Cell Viability Assay
Cell viability was assessed by a propidium iodide (PI) assay
performed in each group after 2 h reoxygenation. PI (Sigma,
St. Louis, MO, USA) was chosen, as it stains cells with
severely impaired membrane integrity and it does not neces-
sitate dissociation of the cells. Briefly, the growth medium was
removed, cells were washed with PBS twice and incubated
with PI (50 lM) for 7 min. Each experiment included a dig-
itonin (10-4 M) (Sigma, St. Louis, MO, USA) treated positive
control well and PI control (mESC-derived cardiomyocytes
without treatment and stained for PI for 7 min) (Fig. 2). Then
PI solution was replaced with fresh PBS and fluorescence
intensity of each EB was detected by fluorescent plate reader
(FluoStar Optima, BMG Labtech). Fluorescence intensity was
measured in well scanning mode (scan matrix: 10 9 10; scan
diameter: 10 mm; bottom optic; no of flashes/scan point: 3;
temp. 37 C; excitation wavelength: 544 nm; emission
wavelength: 610 nm). PI intensity reflecting the cell death was
evaluated on a standard area (21 scan box) in each well placed
to the center of EB. The cardiac myocyte-rich region can be
found predominantly near the edge of the embryonic body.
Therefore, the evaluation of cardiac myocyte rich regions was
performed manually on several plates by detecting GFP
expression driven by the promoter of the early cardiac myo-
cyte marker Nkx2.5. The ratio of cardiac myocyte death was
Fig. 1 Experimental protocol
of SI and reoxygenation in
mESC-derived cardiomyocytes
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the same as the ratio of cell death of all cells found in the
embryonic body. Background fluorescence intensity (dye
control) was subtracted from the fluorescence intensity of each
well after PI staining, and the average intensity of each group
was plotted. The cytoprotective effect of different compounds
was compared to simulated ischemic control groups.
Statistical Analysis
Results are expressed as mean ± SEM. One way analysis
of variance (ANOVA) followed by Fisher’s least signifi-
cant difference (LSD) post-hoc tests was used to determine
differences in mean values between groups. In case com-
parison of two groups, unpaired t test was used. Differences
were considered significant at p \ 0.05.
Results
Cell Viability After SI/Reoxygenation
We applied SI/reoxygenation to mimic ischemia/reperfu-
sion injury in mESC-derived cardiomyocytes. Two and
half hours of SI followed by reoxygenation caused signif-
icantly higher cell death in mESC-derived cardiomyocytes
than time-matched controls kept under normoxic condi-
tions (Fig. 2). SI killed roughly 20–40 % of cells in
embryonic body.
The cytoprotective action of the NO donor SNAP that
activates soluble guanylate cyclase was tested in this model
of SI and reoxygenation-induced cell death in mESC-
derived cardiomyocytes. Cell death was significantly
decreased by SNAP in a concentration-dependent manner
(10-6 and 10-5 M, p \ 0.05) when applied during SI
period (Figs. 3, 4). The contribution of endogenous NO
production of mESC-derived cardiomyocytes to cell death
during SI was tested by administration of the non-selective
NOS inhibitor L-NNA at 10-5 and 10-4 M concentration.
The presence of L-NNA did not influence cell death after SI
(Fig. 5).
BNP, an activator of particulate GC, was also tested
under SI condition at 10-9, 10-8, and 10-7 M concentra-
tions. However, BNP did not influence cell death signifi-
cantly (Fig. 6).
In separate experiments, the downstream pathways of
SNAP-induced protection of mESC-derived cardiomyocytes
were studied. The cytoprotective effect of SNAP (at 10-6 M)
Fig. 2 Cell viability of mESC-derived cardiomyocytes subjected to
normoxia or SI: representative results obtained from one plate.
Background fluorescence intensity is represented by using non-treated
EB?PI in three wells. Pi?digitonin control alone was applied in one
well. Data are mean ± SEM. *p \ 0.05 normoxia versus SI; t test,
n = 5–6 in both groups
Fig. 3 Cell viability indicated by PI staining on mESC-derived cardiomyocytes. Representative fluorescent images of normoxic (a), SI (b), and
SI?SNAP (10-6 M) (c) treated groups showing the amount of dead cells (increased nuclear fluorescence) in mESC-derived cardiomyocytes
Fig. 4 Effect of SNAP on cell viability of mESC-derived cardio-
myocytes. Cell viability of mESC-derived cardiomyocytes subjected
to SI. SNAP administration was applied during SI. Data are
mean ± SEM. *p \ 0.05 versus SI control; one-way ANOVA
followed by Fischer LSD post-hoc test, n = 10–12 in each group
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was attenuated either by simultaneous administration of the
selective PKG inhibitor KT-5823 (6 9 10-8 M) or by
simultaneous administration of KATP channel inhibitor gli-
benclamide (10-6 M). Inhibitors administered alone, or their
vehicle DMSO did not influence cell viability (Fig. 7).
In time-matched normoxic control groups, none of the
above treatment influenced cell viability significantly (data
not shown).
Discussion
In the present study we established an ESC-derived cardiac
myocyte-based in vitro drug screening system and showed
that the NO-donor SNAP was protective against SI/
reoxygenation-induced cell death. Either a selective
inhibitor of PKG or a non-selective inhibitor of KATP
channels interfered with this protection. In contrast to
SNAP, the particulate guanylyl cyclase stimulator BNP had
no effect on cell viability during SI. This is the first dem-
onstration that mESC-derived cardiomyocytes are a useful
tool for screening cytoprotective agents and their cyto-
protective signaling pathways against ischemia/reperfusion
injury.
Currently used cell-based assays based on primary
neonatal cells have limitations for screening cardioprotec-
tive agents, including variability introduced by the isola-
tion procedure and limited proliferation [19]. Adult
cardiomyocytes are suitable to study individual cells,
especially their electrophysiological properties. In addition,
extracellular matrix proteins are required for their main-
tenance which may influence viability during SI [2]. The
cardiomyoblast cell line (H9c2) is widely used for in vitro
drug screening. However, H9c2 cells differ from primary
cardiomyocytes, e.g., they are lacking spontaneous electric
activity and clearly developed sarcomeric structures [20].
Therefore, advantages of ESC-based assays are the well
reproducible production of contracting myocardial cells
and that they do not require sacrificing a number of
animals.
Therefore, here we validated a mESC-derived cardio-
myocyte-based drug-screening platform using the NO
donor SNAP. SNAP is a well-known cardioprotective
compound. It exerts both early and late preconditioning-like
cardioprotective effect in various models [21, 22] and
attenuates apoptosis in neonatal cardiomyocytes [23].
Accordingly, in the present study, SNAP showed a con-
centration-dependent increase in viability of mESC-derived
cardiomyocytes after SI/reoxygenation. This finding indi-
cates that mESC-derived cardiac myocytes are useful tools
for testing cardioprotective agents and suggests that NO
donors may also be cytoprotective for stem cells implanted
into ischemic areas of the myocardium. It is of interest that
NO has been also shown to promote ESC differentiation and
cardiomyogenesis in mESCs [24].
Fig. 5 Effect of L-NNA on cell viability of mESC-derived cardio-
myocytes. Cell viability of mESC-derived cardiomyocytes subjected
to SI. L-NNA was applied during SI. Data are mean ± SEM;
n = 10–12 in each groups
Fig. 6 Effect of BNP on cell viability of mESC-derived cardiomyo-
cytes. Cell viability of mESC-derived cardiomyocytes subjected to SI.
BNP was applied during SI. Data are mean ± SEM, n = 10–12 in
each groups
Fig. 7 Effect of PKG (KT) and KATP (Glib) inhibitor on cell viability
of mESC-derived cardiomyocytes. Cell viability of mESC-derived
cardiomyocytes subjected to SI. Drugs were applied during SI. Data
are mean ± SEM; *p \ 0.05 versus SI control; one-way ANOVA
followed by Fischer LSD post-hoc test, n = 10–12 in each groups
262 Mol Biotechnol (2014) 56:258–264
123
It has been well established that NO donors including
SNAP exert protective effect against myocardial ischemia–
reperfusion injury via activation of soluble guanylate
cyclase and increased cGMP signaling (see for a review
[25]). We have recently shown that SNAP induces cyto-
protection via the activation of soluble guanylate cyclase in
neonatal cardiomyocytes [10]. However, in our previous
studies the efficacy of SNAP-induced cytoprotection was
more pronounced in neonatal cardiomyocytes than shown
here in mESC-derived cardiomyocytes. This difference is
probably due to the low expression level of soluble gua-
nylyl cyclase and NOS at 6–8-days-old stage of mESC-
derived cardiomyocytes [26]. The latter is in line with our
present results that the NOS inhibitor L-NNA did not affect
cell viability after SI/reoxygenation injury of mESC-
derived cardiomyocytes, showing that endogenous NO is
not involved in cardiocytoprotection.
To test if activation of particulate guanylate cyclase can
increase cell viability similar to SNAP, the effect of BNP
was tested. BNP is a potent cardioprotective peptide, as it is
able to reduce infarct size in rat hearts [16] and to protect
neonatal rat cardiomyocytes against SI/reoxygenation
injury [10]. Interestingly, in our present study, cell viability
was not influenced by either concentration of BNP in
mESC-derived cardiomyocytes. This finding may be due to
a low expression of the BNP specific NPR-A receptor
during mouse ESC differentiation [27].
We further identified cardioprotective signaling path-
ways downstream of cGMP in mESC-derived cardiomyo-
cytes. In the cardiovascular system, at least three classes of
protein targets are activated by cGMP, i.e., cGMP-depen-
dent PKG, cGMP-regulated phosphodiesterases, and cyclic
nucleotide-gated ion channel. In the present study, the
involvement of PKG in SNAP-induced protection was
tested by the PKG inhibitor KT-5823 during SI, which
interferes with PKG at the level of the ATP binding site of
its catalytic domain. KT-5823 alone did not affect the
mESC-derived cardiomyocyte viability, but interfered with
the cytoprotective effect of SNAP, which suggests that the
mechanism of SNAP-induced protection involves PKG.
Our present findings in mESC-derived cardiomyocytes are
consistent with our previous results obtained in neonatal rat
cardiomyocytes, in which the PKG inhibitor abolished the
protective effect of SNAP [10]. However, it is of interest
that Mobley et al. [28] showed that PKG was down-regu-
lated during cardiomyocyte differentiation and inhibition
of PKG produced significantly more differentiated mESC-
derived cardiomyocytes.
Xu et al. [29] demonstrated that exogenous NO mediates
the production of reactive oxygen species and may act via
activation cGMP/PKG signaling, triggering cardiocytopro-
tection by mitochondrial KATP channel opening or by
opening mitochondrial permeability transition pores in
adult rat cardiomyocytes KATP channels have a prominent
role in the electrical excitability of early stage of mESC-
derived cardiomyocytes. Therefore, in the present study, we
investigated the involvement of KATP channels in SNAP-
induced cytoprotection of mESC-derived cardiomyocytes.
The nonselective KATP channel inhibitor glibenclamide
alone did not affect mESC-derived cardiomyocyte viability,
but abolished the cytoprotective effect of SNAP. This is in
line with several earlier reports in other systems [30, 31].
Conclusions
Although the genotypic and phenotypic features of primary
and ESC-derived cardiac myocytes are very similar [31],
here we have shown that these cell types show differences
under different test conditions, such as, e.g., hypoxia and
reoxygenation. These findings emphasize the necessity for
detailed analyses of signal transduction pathways in ESC-
derived cells both in physiological and pathological con-
ditions to establish well-reproducible ESC-derived drug
screening platforms and to predict the viability of these
cells after implantation into an ischemic region of an organ.
Our present study is the first demonstration that mESC-
derived cardiomyocytes subjected to SI/reoxygenation
injury are a useful alternative tool for in vitro screening for
potential cardioprotective agents and to study their down-
stream cellular signaling pathways. The major advantages of
ESC-based screening platforms over other cellular assays are
the well reproducible production of beating myocardial cells
and that it does not require sacrificing a number of animals.
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